Document:

Exhibit 10.5

 

CYNGN INC.

 

2021 INCENTIVE PLAN

 

SECTION 1. PURPOSE

 

The purpose of the CYNGN Inc. 2021 Incentive Plan
is to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company
and its Related Companies by providing them the opportunity to acquire a proprietary interest in the Company and to align their interests
and efforts to the long-term interests of the Company’s stockholders.

 

SECTION 2. DEFINITIONS

 

Certain capitalized terms
used in the Plan have the meanings set forth in Appendix A.

 

SECTION 3. ADMINISTRATION

 

		3.1	Administration of the Plan

 

(a) The
Plan shall be administered by the Board or the Compensation Committee, which shall be composed of two or more directors.

 

(b) The
members of the Compensation Committee shall meet the independence requirements of the applicable stock exchange upon which the Common
Stock is listed. If any member of the Compensation Committee does not qualify as a “non-employee director” for purposes of Rule
16b-3 promulgated under the Exchange Act, then Awards under the Plan for the executive officers of the Company and Nonemployee Directors
shall be administered by a subcommittee consisting of each Compensation Committee member who qualifies as a “non-employee director.”
If fewer than two Compensation Committee members qualify as “non-employee directors,” then the Board shall appoint one or more
other Board members to such subcommittee who do qualify as “non-employee directors,” so that the subcommittee will at all times
consist of two or more members all of whom qualify as “non-employee directors” for purposes of Rule 16b-3 promulgated under
the Exchange Act.

 

(c) Notwithstanding
the foregoing, and to the extent consistent with applicable law, the Board or Compensation Committee may also delegate concurrent responsibility
for administering the Plan, including with respect to designated classes of Eligible Persons, to other committees consisting of one or
more members of the Board, subject to such limitations as the Board deems appropriate, except with respect to grants of Awards to Participants
who are subject to Section 16 of the Exchange Act. Members of any such committee shall serve for such term as the Board may determine,
subject to removal by the Board at any time. To the extent consistent with applicable law, the Board or the Compensation Committee may
authorize one or more officers of the Company to grant Awards to designated classes of Eligible Persons, within limits specifically prescribed
by the Board or the Compensation Committee; provided, however, that no such officer shall have or obtain authority to grant Awards to
himself or herself or to any person subject to Section 16 of the Exchange Act. All references in the Plan to the “Committee”
shall be to the Board.

 

     

     

    

 

		3.2	Administration and Interpretation by Committee

 

(a) Except
for the terms and conditions explicitly set forth in the Plan, and to the extent permitted by applicable law, the Committee shall have
full power and exclusive authority, subject to such orders or resolutions not inconsistent with the provisions of the Plan as may from
time to time be adopted by the Board to (i) select the Eligible Persons to whom Awards may from time to time be granted under the
Plan; (ii) determine the type or types of Awards to be granted to each Participant under the Plan; (iii) determine the number
of shares of Common Stock to be covered by each Award granted under the Plan; (iv) determine the terms and conditions of any Award
granted under the Plan; (v) approve the forms of notice or agreement for use under the Plan; (vi) determine whether, to what
extent and under what circumstances Awards may be settled in cash, shares of Common Stock or other property or canceled or suspended;
(vii)  interpret and administer the Plan and any instrument evidencing an Award, notice or agreement executed or entered into under
the Plan; (viii) establish such rules and regulations as it shall deem appropriate for the proper administration of the Plan; (ix) delegate
ministerial duties to such of the Company’s employees as it so determines; and (x) make any other determination and take any other
action that the Committee deems necessary or desirable for administration of the Plan.

 

(b) The
Committee shall have the right, without stockholder approval, to (i) lower the exercise or grant price of an Option or SAR after it is
granted; (ii) cancel an Option or SAR at a time when its exercise or grant price exceeds the Fair Market Value of the underlying stock,
in exchange for cash, another option or stock appreciation right, restricted stock, or other equity award; or (iii) take any other action
that is treated as a repricing under generally accepted accounting principles.

 

(c) The
effect on the vesting of an Award of a Company-approved leave of absence or a Participant’s reduction in hours of employment or service
or working less than full-time shall be determined by the Company’s chief human resources officer or other person performing that function
or, with respect to directors or executive officers, by the Compensation Committee, whose determination shall be final.

 

(d) Decisions
of the Committee shall be final, conclusive and binding on all persons, including the Company, any Participant, any stockholder and any
Eligible Person. A majority of the members of the Committee may determine its actions.

 

SECTION 4. SHARES SUBJECT TO THE PLAN

 

		4.1	Authorized Number of Shares

 

Subject to adjustment from time to time as provided
in Section 15.1, the aggregate maximum number of shares of Common Stock available for issuance under the Plan shall be:

 

(a) 1,500,000
shares; plus

 

(b) an
annual increase to be added as of the first day of the Company’s fiscal year beginning in 2022 equal to the least of (i) 5%
of the outstanding Common Stock on a fully diluted basis as of the end of the Company’s immediately preceding fiscal year, (ii) 1,000,000 shares,
and (iii) a lesser amount determined by the Board; provided, however, that any shares from any such increases in previous years that
are not actually issued shall continue to be available for issuance under the Plan; plus

 

    2

     

    

 

(c) (i) any
authorized shares reserved and available for issuance, and not issued or subject to outstanding awards, under the Company’s 2013 Equity
Incentive Plan (the “Prior Plan”) on the Effective Date shall cease to be set aside and reserved for issuance
pursuant to the Prior Plan, effective on the Effective Date, and shall instead be set aside and reserved for issuance pursuant to the
Plan and (ii) any shares subject to outstanding awards under the Prior Plan on the Effective Date that cease to be subject to such awards
following the Effective Date (other than by reason of exercise or settlement of the awards to the extent they are exercised for or settled
in vested or nonforfeitable shares) shall cease to be set aside or reserved for issuance pursuant to the Prior Plan, effective on the
date upon which they cease to be so subject to such awards, and shall instead be set aside and reserved for issuance pursuant to the Plan,
up to an aggregate maximum of 8,500,000 shares pursuant to clauses (i) and (ii) of this paragraph (c), subject to adjustment from
time to time as provided in Section 15.1.

 

Shares issued under the Plan shall be drawn from
authorized and unissued shares or shares now held or subsequently acquired by the Company as treasury shares.

 

		4.2	Share Usage

 

(a) Shares
of Common Stock covered by an Award shall not be counted as used unless and until they are actually issued and delivered to a Participant.
If any Award lapses, expires, terminates or is canceled prior to the issuance of shares thereunder, is settled in cash in lieu of shares
of Common Stock, or if shares of Common Stock are issued under the Plan to a Participant and thereafter are forfeited to or otherwise
reacquired by the Company, the shares subject to such Awards and the forfeited or reacquired shares shall again be available for issuance
under the Plan. Any shares of Common Stock (i) tendered by a Participant or retained by the Company as full or partial payment to the
Company for the purchase price of an Award or to satisfy tax withholding obligations in connection with an Award, or (ii) covered
by an Award that is settled in cash, or in a manner such that some or all of the shares of Common Stock covered by the Award are not issued,
shall be available for Awards under the Plan. The number of shares of Common Stock available for issuance under the Plan shall not be
reduced to reflect any dividends or dividend equivalents that are reinvested into additional shares of Common Stock or credited as additional
shares of Common Stock subject or paid with respect to an Award. Notwithstanding the foregoing, any shares of Common Stock tendered by
a Participant or retained by the Company as full or partial payment to the Company for the exercise or purchase price of an Award, or
to satisfy tax withholding obligations in connection with an Award, shall not again be available for Awards under the Plan.

 

(b) The
Committee shall also, without limitation, have the authority to grant Awards as an alternative to or as the form of payment for grants
or rights earned or due under other compensation plans or arrangements of the Company.

 

(c) Notwithstanding
any other provision of the Plan to the contrary, the Committee may grant Substitute Awards under the Plan. Substitute Awards shall not
reduce the number of shares authorized for issuance under the Plan. In the event that an Acquired Entity has shares available for awards
or grants under one or more preexisting plans not adopted in contemplation of such acquisition or combination, then, to the extent determined
by the Board or the Committee, the shares available for grant pursuant to the terms of such preexisting plans (as adjusted, to the extent
appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine
the consideration payable to holders of securities of the entities that are parties to such acquisition or combination) may be used for
Awards under the Plan and shall not reduce the number of shares of Common Stock authorized for issuance under the Plan; provided, however,
that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of such
preexisting plans, absent the acquisition or combination, and shall only be made to individuals who were not employees or directors of
the Company or a Related Company prior to such acquisition or combination. In the event that a written agreement between the Company and
an Acquired Entity pursuant to which a merger or consolidation is completed is approved by the Board and that agreement sets forth the
terms and conditions of the substitution for or assumption of outstanding awards of the Acquired Entity, those terms and conditions shall
be deemed to be the action of the Committee without any further action by the Committee, except as may be required for compliance with
Rule 16b-3 under the Exchange Act, and the persons holding such awards shall be deemed to be Participants

 

    3

     

    

 

(d) Notwithstanding
any other provisions in this Section 4.2 to the contrary, the maximum number of shares that may be issued upon the exercise of Incentive
Stock Options shall equal the aggregate share number stated in Section 4.1, subject to adjustment as provided in Section 15.1.

 

SECTION 5. ELIGIBILITY

 

An Award may be granted to any employee, officer
or director of the Company or a Related Company whom the Committee from time to time selects. An Award may also be granted to any consultant,
agent, advisor or independent contractor for bona fide services rendered to the Company or any Related Company that (a) are not in
connection with the offer and sale of the Company’s securities in a capital-raising transaction and (b) do not directly or indirectly
promote or maintain a market for the Company’s securities.

 

SECTION 6. AWARDS

 

		6.1	Form, Grant and Settlement of Awards

 

The Committee shall have the authority, in its
sole discretion, to determine the type or types of Awards to be granted under the Plan. Such Awards may be granted either alone or in
addition to or in tandem with any other type of Award. Any Award settlement may be subject to such conditions, restrictions and contingencies
as the Committee shall determine.

 

		6.2	Evidence of Awards

 

Awards granted under the Plan shall be evidenced
by a written, including an electronic, instrument that shall contain such terms, conditions, limitations and restrictions as the Committee
shall deem advisable and that are not inconsistent with the Plan.

 

    4

     

    

 

		6.3	Deferrals

 

The Committee may permit or
require a Participant to defer receipt of the payment of any Award. If any such deferral election is permitted or required, the Committee,
in its sole discretion, shall establish rules and procedures for such payment deferrals, which may include the grant of additional Awards
or provisions for the payment or crediting of interest or dividend equivalents, including converting such credits to deferred stock unit
equivalents. Deferral of any Award or payment thereunder shall comply with all applicable law, rules and regulations, and shall satisfy
either the requirements for exemption from Section 409A or the requirements of Section 409A as determined by the Committee prior to such
deferral.

 

		6.4	Dividends and Distributions

 

Participants may, if the Committee
so determines, be credited with dividends or dividend equivalents paid with respect to shares of Common Stock underlying an Award in a
manner determined by the Committee in its sole discretion. The Committee may apply any restrictions to the dividends or dividend equivalents
that the Committee deems appropriate. The Committee, in its sole discretion, may determine the form of payment of dividends or dividend
equivalents, including cash, shares of Common Stock, Restricted Stock or Stock Units. Notwithstanding the foregoing, any dividends or
dividend equivalents credited to an Award shall accrue and be paid only to the extent the Award becomes vested or payable. Also, notwithstanding
the foregoing, crediting of dividends or dividend equivalents must comply with or qualify for an exemption under Section 409A.

 

SECTION 7. OPTIONS

 

		7.1	Grant of Options

 

The Committee may grant Options designated as
Incentive Stock Options or Nonqualified Stock Options.

 

		7.2	Option Exercise Price

 

Options shall be granted with an exercise price
per share not less than 100% of the Fair Market Value of the Common Stock on the Grant Date (and not less than the minimum exercise price
required by Section 422 of the Code with respect to Incentive Stock Options), except in the case of Substitute Awards.

 

		7.3	Term of Options

 

Subject to earlier termination in accordance with
the terms of the Plan and the instrument evidencing the Option, the maximum term of an Option (the “Option Term”)
shall be ten years from the Grant Date. For Incentive Stock Options, the Option Term shall be as specified in Section 8.4.

 

    5

     

    

 

		7.4	Exercise of Options

 

(a) The
Committee shall establish and set forth in each instrument that evidences an Option the time at which, or the installments in which, the
Option shall vest and become exercisable, any of which provisions may be waived or modified by the Committee at any time. If not so established
in the instrument evidencing the Option, the Option shall vest and become exercisable according to the following schedule, which may be
waived or modified by the Committee at any time:

 

	

    Period of Participant’s Continuous

Employment or Service with the

Company or Its Related Companies

from the Vesting Commencement Date

	 	
    Portion of Total Option That

Is Vested and Exercisable

	 	 	 
	After 1 year	 	1/4th
	 	 	 
	After each additional one-month period of continuous service completed thereafter	 	An additional 1/48th
	 	 	 
	After 4 years	 	100%

 

(b) To
the extent an Option has vested and become exercisable, the Option may be exercised in whole or from time to time in part by delivery
to or as directed or approved by the Company of a properly executed stock option exercise agreement or notice, in a form and in accordance
with procedures established by the Committee, setting forth the number of shares with respect to which the Option is being exercised,
the restrictions imposed on the shares purchased under such exercise agreement or notice, if any, and such representations and agreements
as may be required by the Committee, accompanied by payment in full as described in Section 7.5. An Option may be exercised only
for whole shares and may not be exercised for less than a reasonable number of shares at any one time, as determined by the Committee.

 

		7.5	Payment of Exercise Price

 

The exercise price for shares purchased under
an Option shall be paid in full to the Company by delivery of consideration equal to the product of the Option exercise price and the
number of shares purchased. Such consideration must be paid before the Company will issue the shares being purchased and must be in a
form or a combination of forms acceptable to the Committee for that purchase, which forms may include:

 

(a) cash;

 

(b) check
or wire transfer;

 

(c) having
the Company withhold shares of Common Stock that would otherwise be issued on exercise of a Nonqualified Stock Option that have an aggregate
Fair Market Value equal to the aggregate exercise price of the shares being purchased under the Option;

 

    6

     

    

 

(d) tendering
(either actually or, if and for as long as the Common Stock is registered under Section 12(b) or 12(g) of the Exchange Act,
by attestation) shares of Common Stock owned by the Participant that have an aggregate Fair Market Value equal to the aggregate exercise
price of the shares being purchased under the Option;

 

(e) if
and so long as the Common Stock is registered under Section 12(b) or 12(g) of the Exchange Act, and to the extent permitted by law,
delivery of a properly executed exercise agreement or notice, together with irrevocable instructions to a brokerage firm designated or
approved by the Company to deliver promptly to the Company the aggregate amount of proceeds to pay the Option exercise price and any tax
withholding obligations that may arise in connection with the exercise, all in accordance with the regulations of the Federal Reserve
Board; or

 

(f) such
other consideration as the Committee may permit.

 

		7.6	Effect of Termination of Service

 

(a) The
Committee shall establish and set forth in each instrument that evidences an Option whether the Option shall continue to be exercisable,
and the terms and conditions of such exercise, after a Termination of Service, any of which provisions may be waived or modified by the
Committee at any time. If not so established and set forth in the instrument evidencing the Option, the Option shall be exercisable according
to the following terms and conditions, which may be waived or modified by the Committee at any time:

 

		(i)	Any portion of an Option that is not vested and exercisable on
the date of a Participant’s Termination of Service shall expire on such date.

 

		(ii)	Any portion of an Option that is vested and exercisable on the
date of a Participant’s Termination of Service shall expire on the earliest to occur of:

 

		(1)	if the Participant’s Termination of Service occurs for reasons
other than Cause, Retirement, Disability or death, the date that is three months after such Termination of Service;

 

		(2)	if the Participant’s Termination of Service occurs by reason of
Retirement, Disability or death, the one-year anniversary of such Termination of Service; and

 

		(3)	the Option Expiration Date.

 

(b) Notwithstanding
the foregoing, if a Participant dies after the Participant’s Termination of Service but while an Option is otherwise exercisable, the
portion of the Option that is vested and exercisable on the date of such Termination of Service shall expire upon the earlier to occur
of (y) the Option Expiration Date and (z) the one-year anniversary of the date of death, unless the Committee determines otherwise.

 

(c) Also
notwithstanding the foregoing, in case a Participant’s Termination of Service occurs for Cause, all Options granted to the Participant,
whether vested or unvested, shall automatically expire and terminate upon first notification to the Participant of such termination, unless
the Committee determines otherwise. If a Participant’s employment or service relationship with the Company is suspended pending an investigation
of whether the Participant shall be terminated for Cause, all the Participant’s rights under any Option shall likewise be suspended during
the period of investigation. If any facts that would constitute termination for Cause are discovered after a Participant’s Termination
of Service, any Option then held by the Participant may be immediately terminated by the Committee, in its sole discretion.

 

    7

     

    

 

(d) If
the exercise of the Option following a Participant’s Termination of Service, but while the Option is otherwise exercisable, would be prohibited
solely because the issuance of Common Stock would violate either the registration requirements under the Securities Act or the Company’s
insider trading policy, then the Option shall remain exercisable until the earlier of (i) the Option Expiration Date or (ii) the
expiration of a period of three months (or such longer period of time as determined by the Committee in its sole discretion) after the
Participant’s Termination of Service during which the exercise of the Option would not be in violation of such Securities Act or insider
trading policy requirements.

 

SECTION 8. INCENTIVE STOCK OPTION LIMITATIONS

 

Notwithstanding any other provision of the Plan
to the contrary, the terms and conditions of any Incentive Stock Options shall in addition comply in all respects with Section 422
of the Code or any successor provision, and any applicable regulations thereunder, including, to the extent required thereunder, the following:

 

		8.1	Dollar Limitation

 

To the extent the aggregate Fair Market Value
(determined as of the Grant Date) of Common Stock with respect to which a Participant’s Incentive Stock Options become exercisable for
the first time during any calendar year (under the Plan and all other stock option plans of the Company and its parent and subsidiary
corporations) exceeds $100,000, such portion in excess of $100,000 shall be treated as a Nonqualified Stock Option. In the event the Participant
holds two or more such Options that become exercisable for the first time in the same calendar year, such limitation shall be applied
on the basis of the order in which such Options are granted.

 

		8.2	Eligible Employees

 

Individuals who are not employees of the Company
or one of its parent or subsidiary corporations may not be granted Incentive Stock Options.

 

		8.3	Exercise Price

 

Incentive Stock Options shall be granted with
an exercise price per share not less than 100% of the Fair Market Value of the Common Stock on the Grant Date and, in the case of an Incentive
Stock Option granted to a Participant who owns more than 10% of the total combined voting power of all classes of the stock of the Company
or of its parent or subsidiary corporations (a “Ten Percent Stockholder”), shall be granted with an exercise price
per share not less than 110% of the Fair Market Value of the Common Stock on the Grant Date. The determination of more than 10% ownership
shall be made in accordance with Section 422 of the Code.

 

    8

     

    

 

		8.4	Option Term

 

Subject to earlier termination in accordance with
the terms of the Plan and the instrument evidencing the Option, the maximum term of an Incentive Stock Option shall not exceed ten years,
and in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, shall not exceed five years.

 

		8.5	Exercisability

 

An Option designated as an Incentive Stock Option
shall cease to qualify for favorable tax treatment as an Incentive Stock Option to the extent it is exercised (if permitted by the terms
of the Option) (a) more than three months after the date of a Participant’s termination of employment if termination was for reasons
other than death or disability, (b) more than one year after the date of a Participant’s termination of employment if termination
was by reason of disability, or (c) more than six months following the first day of a Participant’s leave of absence that exceeds
three months, unless the Participant’s reemployment rights are guaranteed by statute or contract.

 

		8.6	Taxation of Incentive Stock Options

 

In order to obtain certain tax benefits afforded
to Incentive Stock Options under Section 422 of the Code, the Participant must hold the shares acquired upon the exercise of an Incentive
Stock Option for two years after the Grant Date and one year after the date of exercise. A Participant may be subject to the alternative
minimum tax at the time of exercise of an Incentive Stock Option. The Participant shall give the Company prompt notice of any disposition
of shares acquired on the exercise of an Incentive Stock Option prior to the expiration of such holding periods.

 

		8.7	Code Definitions

 

For the purposes of this Section 8, “disability,”
“parent corporation” and “subsidiary corporation” shall have the meanings attributed to those terms for purposes of
Section 422 of the Code.

 

		8.8	Stockholder Approval

 

If the stockholders of the Company do not approve
the Plan within 12 months after the Board’s adoption of the Plan (or the Board’s adoption of any amendment to the Plan that constitutes
the adoption of a new plan for purposes of Section 422 of the Code), Incentive Stock Options granted under the Plan after the date of
the Board’s adoption (or approval) will be treated as Nonqualified Stock Options. No Incentive Stock Options may be granted more than
ten years after the earlier of the approval of the Plan by the Board or the stockholders (including any such approval of an amendment
to the Plan that constitutes the adoption of a new plan for purposes of Section 422 of the Code).

 

SECTION 9. STOCK APPRECIATION RIGHTS

 

		9.1	Grant of Stock Appreciation Rights

 

The Committee may grant Stock Appreciation Rights
to Participants at any time on such terms and conditions as the Committee shall determine in its sole discretion. A SAR may be granted
in tandem with an Option (“tandem SAR”) or alone (“freestanding SAR”). The grant price
of a tandem SAR shall be equal to the exercise price of the related Option. The grant price of a freestanding SAR shall be established
in accordance with procedures for Options set forth in Section 7.2. A SAR may be exercised upon such terms and conditions and for
the term as the Committee determines in its sole discretion; provided, however, that, subject to earlier termination in accordance with
the terms of the Plan and the instrument evidencing the SAR, the maximum term of a freestanding SAR shall be ten years, and in the case
of a tandem SAR, (a) the term shall not exceed the term of the related Option and (b) the tandem SAR may be exercised for all
or part of the shares subject to the related Option upon the surrender of the right to exercise the equivalent portion of the related
Option, except that the tandem SAR may be exercised only with respect to the shares for which its related Option is then exercisable.

 

    9

     

    

 

		9.2	Payment of SAR Amount

 

Upon the exercise of a SAR, a Participant shall
be entitled to receive payment in an amount determined by multiplying: (a) the difference between the Fair Market Value of the Common
Stock on the date of exercise over the grant price of the SAR by (b) the number of shares with respect to which the SAR is exercised.
At the discretion of the Committee as set forth in the instrument evidencing the Award, the payment upon exercise of a SAR may be in cash,
in shares, in some combination thereof or in any other manner approved by the Committee in its sole discretion.

 

	9.3	Waiver of Restrictions

 

The Committee, in its sole discretion, may waive
any other terms, conditions or restrictions on any SAR under such circumstances and subject to such terms and conditions as the Committee
shall deem appropriate.

 

SECTION 10. STOCK AWARDS, RESTRICTED
STOCK AND STOCK UNITS

 

		10.1	Grant of Stock Awards, Restricted Stock and Stock Units

 

The Committee may grant Stock Awards, Restricted
Stock and Stock Units on such terms and conditions and subject to such repurchase or forfeiture restrictions, if any, which may be based
on continuous service with the Company or a Related Company or the achievement of any performance goals, as the Committee shall determine
in its sole discretion, which terms, conditions and restrictions shall be set forth in the instrument evidencing the Award.

 

		10.2	Vesting of Restricted Stock and Stock Units

 

Upon the satisfaction of any terms, conditions
and restrictions prescribed with respect to Restricted Stock or Stock Units, or upon a Participant’s release from any terms, conditions
and restrictions on Restricted Stock or Stock Units, as determined by the Committee, (a) the shares covered by each Award of Restricted
Stock shall become freely transferable by the Participant subject to the terms and conditions of the Plan, the instrument evidencing the
Award, and applicable securities laws, and (b) Stock Units shall be paid in shares of Common Stock or, if set forth in the instrument
evidencing the Awards, in cash or a combination of cash and shares of Common Stock. Any fractional shares subject to such Awards shall
be paid to the Participant in cash.

 

    10

     

    

 

		10.3	Waiver of Restrictions

 

The Committee, in its sole discretion, may waive
the repurchase or forfeiture period and any other terms, conditions or restrictions on any Restricted Stock or Stock Unit under such circumstances
and subject to such terms and conditions as the Committee shall deem appropriate.

 

SECTION 11. PERFORMANCE AWARDS

 

		11.1	Performance Shares

 

The Committee may grant Awards of Performance
Shares, designate the Participants to whom Performance Shares are to be awarded and determine the number of Performance Shares and the
terms and conditions of each such Award. Performance Shares shall consist of a unit valued by reference to a designated number of shares
of Common Stock, the value of which may be paid to the Participant by delivery of shares of Common Stock or, if set forth in the instrument
evidencing the Award, of such property as the Committee shall determine, including, without limitation, cash, shares of Common Stock,
other property, or any combination thereof, upon the attainment of performance goals, as established by the Committee, and other terms
and conditions specified by the Committee. Notwithstanding the foregoing, and subject to Section 18.5, the amount to be paid under
an Award of Performance Shares may be adjusted on the basis of such further consideration as the Committee shall determine in its sole
discretion.

 

		11.2	Performance Units

 

The Committee may grant Awards of Performance
Units, designate the Participants to whom Performance Units are to be awarded and determine the number of Performance Units and the terms
and conditions of each such Award. Performance Units shall consist of a unit valued by reference to a designated amount of property other
than shares of Common Stock, which value may be paid to the Participant by delivery of such property as the Committee shall determine,
including, without limitation, cash, shares of Common Stock, other property, or any combination thereof, upon the attainment of performance
goals, as established by the Committee, and other terms and conditions specified by the Committee. Notwithstanding the foregoing, and
subject to Section 18.5, the amount to be paid under an Award of Performance Units may be adjusted on the basis of such further consideration
as the Committee shall determine in its sole discretion.

 

SECTION 12. OTHER STOCK OR CASH-BASED
AWARDS

 

Subject to the terms of the Plan and such other
terms and conditions as the Committee deems appropriate, the Committee may grant other incentives payable in cash or in shares of Common
Stock under the Plan.

 

SECTION 13. WITHHOLDING

 

(a) The
Company may require the Participant to pay to the Company or a Related Company, as applicable, the amount of (i) any taxes that the
Company or a Related Company is required by applicable federal, state, local or foreign law to withhold with respect to the grant, vesting
or exercise of an Award (“tax withholding obligations”) and (ii) any amounts due from the Participant to
the Company or to any Related Company (“other obligations”). Notwithstanding any other provision of the Plan to
the contrary, the Company shall not be required to issue any shares of Common Stock or otherwise settle an Award under the Plan until
such tax withholding obligations and other obligations are satisfied.

 

    11

     

    

 

(b) The
Committee, in its sole discretion, may permit or require a Participant to satisfy all or part of the Participant’s tax withholding obligations
and other obligations by (i) paying cash to the Company or a Related Company, as applicable, (ii) having the Company or a Related
Company, as applicable, withhold an amount from any cash amounts otherwise due or to become due from the Company or a Related Company
to the Participant, (iii) having the Company withhold a number of shares of Common Stock that would otherwise be issued to the Participant
(or become vested, in the case of Restricted Stock) having a Fair Market Value equal to the tax withholding obligations and other obligations,
or (iv) surrendering a number of shares of Common Stock the Participant already owns having a value equal to the tax withholding
obligations and other obligations. The value of the shares so withheld or tendered may not exceed the employer’s applicable minimum required
tax withholding rate or such other applicable rate as is necessary to avoid adverse treatment for financial accounting purposes, as determined
by the Plan Administrator in its sole discretion.

 

SECTION 14. ASSIGNABILITY

 

No Award or interest in an Award may be sold,
assigned, pledged (as collateral for a loan or as security for the performance of an obligation or for any other purpose) or transferred
by a Participant or made subject to attachment or similar proceedings otherwise than by will or by the applicable laws of descent and
distribution, except to the extent, at the discretion of the Committee, the instrument evidencing the Award permits the Participant to
designate one or more beneficiaries on a Company-approved form who may exercise the Award or receive payment under the Award after the
Participant’s death. Notwithstanding the foregoing, the Committee, in its sole discretion, may permit a Participant to assign or transfer
an Award without consideration, subject to such terms and conditions as the Committee shall specify.

 

SECTION 15. ADJUSTMENTS

 

		15.1	Adjustment of Shares

 

(a) In
the event that, at any time or from time to time, a stock dividend, stock split, spin off, combination or exchange of shares, recapitalization,
merger, consolidation, distribution to stockholders other than a normal cash dividend that has a material effect on the price of Common
Stock, or other similar occurrence occurs, or a change in the Company’s corporate or capital structure results in (i) outstanding shares
of Common Stock, or any securities exchanged therefor or received in their place, being exchanged for a different number or kind of securities
of the Company or (ii) new, different or additional securities of the Company or any other company being received by the holders of shares
of Common Stock, then the Committee shall make proportional adjustments as it, in its sole discretion, deems appropriate in: (A) the
maximum number and kind of securities available for issuance under the Plan; (B) the maximum number and kind of securities issuable
as Incentive Stock Options as set forth in Section 4.2; (C) the maximum numbers and kind of securities set forth in Section
16.3; (D) the maximum number and kind of securities set forth in Section 4.3; and (E) the number and kind of securities that are subject
to any outstanding Award and, if applicable, the per share price of such securities.

 

    12

     

    

 

(b) Adjustments,
if any, and any determinations or interpretations made by the Committee as to whether any adjustment shall be made, including any determination
of whether a distribution is other than a normal cash dividend or is a cash dividend that will have a material effect on the price of
issued shares, and the terms of any of the foregoing adjustments shall be conclusive and binding.

 

(c) Notwithstanding
the foregoing, the issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class,
for cash or property, or for labor or services rendered, either upon direct sale or upon the exercise of rights or warrants to subscribe
therefor, or upon conversion of shares or obligations of the Company convertible into such shares or other securities, shall not affect,
and no adjustment by reason thereof shall be made with respect to, outstanding Awards. Also notwithstanding the foregoing, a dissolution
or liquidation of the Company or a Change in Control shall not be governed by this Section 15.1 but shall be governed by Sections 15.2
and 15.3, respectively.

 

		15.2	Dissolution or Liquidation

 

To the extent not previously exercised or settled,
and unless otherwise determined by the Committee in its sole discretion, Awards shall terminate immediately prior to the dissolution or
liquidation of the Company. To the extent a vesting condition, forfeiture provision or repurchase right applicable to an Award has not
been waived by the Committee, the Award shall be forfeited immediately prior to the consummation of the dissolution or liquidation.

 

		15.3	Change of Control

 

(a) Notwithstanding
any other provision of the Plan to the contrary, unless the Committee determines otherwise with respect to a particular Award in the instrument
evidencing the Award or in a written employment, services or other agreement between the Participant and the Company or a Related Company,
in the event of a Change of Control, if and to the extent an outstanding Award is not converted, assumed, substituted for or replaced
by the Successor Company, then such Award shall terminate upon effectiveness of the Change of Control. Prior to the Change of Control,
the Plan Administrator may approve accelerated vesting and/or lapse of forfeiture or repurchase restrictions with respect to all or a
portion of the unvested portions of such Awards, any such determinations to be made by the Plan Administrator in its sole discretion.
If and to the extent the Successor Company converts, assumes, substitutes for or replaces an outstanding Award, all vesting and/or exercisability
restrictions and/or forfeiture and/or repurchase provisions applicable to such Award shall continue with respect to any shares of the
Successor Company or other consideration that may be received with respect to such Award. Without the consent of any Participant, the
Plan Administrator may dispose of Awards that are not vested as of the effective date of such Change of Control in any manner permitted
by applicable laws, including (without limitation) the cancellation of such Awards without the payment of any consideration.

 

(b) For
the purposes of Section 15.3(a), an Award shall be considered converted, assumed, substituted for or replaced by the Successor Company
if following the Change of Control the Award confers the right to purchase or receive, for each share of Common Stock subject to the Award
immediately prior to the Change of Control, the consideration (whether stock, cash, or other securities or property) received in the Change
of Control by holders of Common Stock for each share held on the effective date of the transaction (and if holders were offered a choice
of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares); provided, however, that if
such consideration received in the Change of Control is not solely common stock of the Successor Company, the Committee may, with the
consent of the Successor Company, provide for the consideration to be received pursuant to the Award, for each share of Common Stock subject
thereto, to be solely common stock of the Successor Company substantially equal in fair market value to the per share consideration received
by holders of Common Stock in the Change of Control. The determination of such substantial equality of value of consideration shall be
made by the Committee, and its determination shall be conclusive and binding.

 

    13

     

    

 

(c) Notwithstanding
the foregoing, the Committee, in its sole discretion, may instead provide in the event of a Change of Control that a Participant’s outstanding
Awards shall terminate upon or immediately prior to such Change of Control and that each such Participant shall be entitled to receive,
in exchange therefor, a cash payment equal to the amount (if any) by which (i) the Acquisition Price multiplied by the number of
shares of Common Stock subject to such outstanding Awards (either to the extent (if any) then vested and exercisable, or subject to restrictions
and/or forfeiture provisions, or whether or not then vested and exercisable, or subject to restrictions and/or forfeiture provisions,
as determined by the Committee in its sole discretion) exceeds (ii) if applicable, the respective aggregate exercise, grant or purchase
price payable with respect to shares of Common Stock subject to such Awards.

 

(d) For
the avoidance of doubt, nothing in this Section 15.3 requires all Awards, or portions of Awards, to be treated similarly.

 

		15.4	Further Adjustment of Awards

 

Subject to Sections 15.2 and 15.3, the Committee
shall have the discretion, exercisable at any time before a sale, merger, consolidation, reorganization, liquidation, dissolution or other
similar transaction, as defined by the Committee, to take such further action as it determines to be necessary or advisable with respect
to Awards. Such authorized action may include (but shall not be limited to) establishing, amending or waiving the type, terms, conditions
or duration of, or restrictions on, Awards so as to provide for earlier, later, extended or additional time for exercise, lifting restrictions
and other modifications, and the Committee may take such actions with respect to all Participants, to certain categories of Participants
or only to individual Participants. The Committee may take such action before or after granting Awards to which the action relates and
before or after any public announcement with respect to such sale, merger, consolidation, reorganization, liquidation, dissolution or
other similar transaction that is the reason for such action.

 

		15.5	No Limitations

 

The grant of Awards shall in no way affect the
Company’s right to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve,
liquidate or sell or transfer all or any part of its business or assets.

 

    14

     

    

 

		15.6	Fractional Shares

 

In the event of any adjustment in the number of
shares covered by any Award, each such Award shall cover only the number of full shares resulting from such adjustment, and any fractional
shares resulting from such adjustment shall be disregarded.

 

		15.7	Section 409A

 

Subject to Section 18.5, but notwithstanding
any other provision of the Plan to the contrary, (a) any adjustments made pursuant to this Section 15 to Awards that are considered
“deferred compensation” within the meaning of Section 409A shall be made in compliance with the requirements of Section 409A
and (b) any adjustments made pursuant to this Section 15 to Awards that are not considered “deferred compensation”
subject to Section 409A shall be made in such a manner as to ensure that after such adjustment the Awards either (i) continue
not to be subject to Section 409A or (ii) comply with the requirements of Section 409A.

 

SECTION 16. MARKET STANDOFF

 

(a) In
the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed
under the Securities Act, including the Company’s initial public offering, a Participant shall not sell, make any short sale of, loan,
hypothecate, pledge, grant any option for the purchase of, or otherwise dispose of or transfer for value or otherwise agree to engage
in any of the foregoing transactions with respect to any securities of the Company however or whenever acquired (except for those being
registered) without the prior written consent of the Company or its underwriters. Such limitations shall be in effect for such period
of time as may be requested by the Company or such underwriters; provided, however, that in no event shall such period exceed (i) 180 days
after the effective date of the registration statement for such public offering or (ii) such longer period requested by the underwriters
as is necessary to comply with regulatory restrictions on the publication of research reports (including, but not limited to, FINRA Rule
2241, or any amendments or successor rules). Participant shall execute an agreement reflecting the limitation of this Section 16 as may
be requested by the underwriters at the time of such public offering. The limitations of this Section 16 shall in all events terminate
two years after the effective date of the Company’s initial public offering.

 

(b) In
the event of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the
Company’s outstanding Common Stock effected as a class without the Company’s receipt of consideration, any new, substituted or additional
securities distributed with respect to the shares issued under the Plan shall be immediately subject to the provisions of this Section 16,
to the same extent the shares issued under the Plan are at such time covered by such provisions.

 

In order to enforce the limitations of this Section 16,
the Company may impose stop-transfer instructions with respect to the shares until the end of the applicable standoff period.

 

    15

     

    

 

SECTION 17. AMENDMENT AND TERMINATION

 

		17.1	Amendment, Suspension or Termination

 

The Board may amend, suspend or terminate the
Plan or any portion of the Plan at any time and in such respects as it shall deem advisable; provided, however, that, to the extent required
by applicable law, regulation or stock exchange rule, stockholder approval shall be required for any amendment to the Plan. Subject to
Section 17.3, the Board may amend the terms of any outstanding Award, prospectively or retroactively.

 

		17.2	Term of the Plan

 

The Plan shall have no fixed expiration date.
After the Plan is terminated, no future Awards may be granted under the Plan, but Awards previously granted shall remain outstanding in
accordance with their applicable terms and conditions and the Plan’s terms and conditions.

 

		17.3	Consent of Participant

 

(a) The
amendment, suspension or termination of the Plan or a portion thereof or the amendment of an outstanding Award shall not, without the
Participant’s consent, materially adversely affect any rights under any Award theretofore granted to the Participant under the Plan. Any
change or adjustment to an outstanding Incentive Stock Option shall not, without the consent of the Participant, be made in a manner so
as to constitute a “modification” that would cause such Incentive Stock Option to fail to continue to qualify as an Incentive
Stock Option. Notwithstanding the foregoing, any adjustments made pursuant to Section 15 shall not be subject to these restrictions.

 

(b) Subject
to Section 18.5, but notwithstanding any other provision of the Plan to the contrary, the Board shall have broad authority to amend the
Plan or any outstanding Award without the consent of any Participant to the extent the Board deems necessary or advisable to comply with,
or take into account, changes in applicable tax laws, securities laws, accounting rules or other applicable law, rule or regulation.

 

SECTION 18. GENERAL

 

		18.1	No Individual Rights

 

(a) No
individual or Participant shall have any claim to be granted any Award under the Plan, and the Company has no obligation for uniformity
of treatment of Participants under the Plan.

 

(b) Furthermore,
nothing in the Plan or any Award granted under the Plan shall be deemed to constitute an employment contract or confer or be deemed to
confer on any Participant any right to continue in the employ of, or to continue any other relationship with, the Company or any Related
Company or limit in any way the right of the Company or any Related Company to terminate a Participant’s employment or other relationship
at any time, with or without cause.

 

    16

     

    

 

		18.2	Issuance of Shares

 

(a) Notwithstanding
any other provision of the Plan to the contrary, the Company shall have no obligation to issue or deliver any shares of Common Stock under
the Plan or make any other distribution of benefits under the Plan unless, in the opinion of the Company’s counsel, such issuance, delivery
or distribution would comply with all applicable laws (including, without limitation, the requirements of the Securities Act or the laws
of any state or foreign jurisdiction) and the applicable requirements of any securities exchange or similar entity.

 

(b) The
Company shall be under no obligation to any Participant to register for offering or resale or to qualify for exemption under the Securities
Act, or to register or qualify under the laws of any state or foreign jurisdiction, any shares of Common Stock, security or interest in
a security paid or issued under, or created by, the Plan, or to continue in effect any such registrations or qualifications if made.

 

(c) As
a condition to the exercise of an Option or any other receipt of Common Stock pursuant to an Award under the Plan, the Company may require
(a) the Participant to represent and warrant at the time of any such exercise or receipt that such shares are being purchased or
received only for the Participant’s own account and without any present intention to sell or distribute such shares and (b) such
other action or agreement by the Participant as may from time to time be necessary to comply with federal, state and foreign securities
laws. At the option of the Company, a stop-transfer order against any such shares may be placed on the official stock books and records
of the Company, and a legend indicating that such shares may not be pledged, sold or otherwise transferred, unless an opinion of counsel
is provided (concurred in by counsel for the Company) stating that such transfer is not in violation of any applicable law or regulation,
may be stamped on stock certificates to ensure exemption from registration. The Committee may also require the Participant to execute
and deliver to the Company a purchase agreement or such other agreement as may be in use by the Company at such time that describes certain
terms and conditions applicable to the shares.

 

(d) To
the extent the Plan or any instrument evidencing an Award provides for issuance of stock certificates to reflect the issuance of shares
of Common Stock, the issuance may be effected on an uncertificated basis, to the extent not prohibited by applicable law or the applicable
rules of any stock exchange.

 

		18.3	Indemnification

 

(a) Each
person who is or shall have been a member of the Board shall be indemnified and held harmless by the Company against and from any loss,
cost, liability or expense that may be imposed upon or reasonably incurred by such person in connection with or resulting from any claim,
action, suit or proceeding to which such person may be a party or in which such person may be involved by reason of any action taken or
failure to act under the Plan and against and from any and all amounts paid by such person in settlement thereof, with the Company’s approval,
or paid by such person in satisfaction of any judgment in any such claim, action, suit or proceeding against such person, unless such
loss, cost, liability or expense is a result of such person’s own willful misconduct or except as expressly provided by statute; provided,
however, that such person shall give the Company an opportunity, at its own expense, to handle and defend the same before such person
undertakes to handle and defend it on such person’s own behalf.

 

    17

     

    

 

(b) The
foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such person may be entitled
under the Company’s certificate of incorporation or bylaws, as a matter of law, or otherwise, or of any power that the Company may have
to indemnify or hold harmless.

 

		18.4	No Rights as a Stockholder

 

Unless otherwise provided by the Committee or
in the instrument evidencing the Award or in a written employment, services or other agreement, no Award, other than a Stock Award or
an Award of Restricted Stock, shall entitle the Participant to any cash dividend, voting or other right of a stockholder unless and until
the date of issuance under the Plan of the shares that are the subject of such Award.

 

		18.5	Compliance with Laws and Regulations

 

(a) In
interpreting and applying the provisions of the Plan, any Option granted as an Incentive Stock Option pursuant to the Plan shall, to the
extent permitted by law, be construed as an “incentive stock option” within the meaning of Section 422 of the Code.

 

(b) The
Plan and Awards granted under the Plan are intended to be exempt from the requirements of Section 409A to the maximum extent possible,
whether pursuant to the short-term deferral exception described in Treasury Regulation Section 1.409A-1(b)(4), the exclusion applicable
to stock options, stock appreciation rights and certain other equity-based compensation under Treasury Regulation Section 1.409A-1(b)(5),
or otherwise. To the extent Section 409A is applicable to the Plan or any Award granted under the Plan, it is intended that the Plan
and any Awards granted under the Plan shall comply with the deferral, payout, plan termination and other limitations and restrictions
imposed under Section 409A. Notwithstanding any other provision of the Plan or any Award granted under the Plan to the contrary, the Plan
and any Award granted under the Plan shall be interpreted, operated and administered in a manner consistent with such intentions; provided,
however, that the Committee makes no representations that Awards granted under the Plan shall be exempt from or comply with Section 409A
and makes no undertaking to preclude Section 409A from applying to Awards granted under the Plan. Without limiting the generality of the
foregoing, and notwithstanding any other provision of the Plan or any Award granted under the Plan to the contrary, with respect to any
payments and benefits under the Plan or any Award granted under the Plan to which Section 409A applies, all references in the Plan
or any Award granted under the Plan to the termination of the Participant’s employment or service are intended to mean the Participant’s
“separation from service,” within the meaning of Section 409A(a)(2)(A)(i) to the extent necessary to avoid subjecting the
Participant to the imposition of any additional tax under Section 409A. In addition, if the Participant is a “specified employee,”
within the meaning of Section 409A, then to the extent necessary to avoid subjecting the Participant to the imposition of any additional
tax under Section 409A, amounts that would otherwise be payable under the Plan or any Award granted under the Plan during the six-month
period immediately following the Participant’s “separation from service,” within the meaning of Section 409A(a)(2)(A)(i),
shall not be paid to the Participant during such period, but shall instead be accumulated and paid to the Participant (or, in the event
of the Participant’s death, the Participant’s estate) in a lump sum on the first business day after the earlier of the date that is six
months following the Participant’s separation from service or the Participant’s death. Notwithstanding any other provision of the Plan
to the contrary, the Committee, to the extent it deems necessary or advisable in its sole discretion, reserves the right, but shall not
be required, to unilaterally amend or modify the Plan and any Award granted under the Plan so that the Award qualifies for exemption from
or complies with Section 409A.

 

    18

     

    

 

		18.6	Participants in Other Countries or Jurisdictions

 

Without amending the Plan, the Committee may grant
Awards to Eligible Persons who are foreign nationals on such terms and conditions different from those specified in the Plan, as may,
in the judgment of the Committee, be necessary or desirable to foster and promote achievement of the purposes of the Plan and shall have
the authority to adopt such modifications, procedures, subplans and the like as may be necessary or desirable to comply with provisions
of the laws or regulations of other countries or jurisdictions in which the Company or any Related Company may operate or have employees
to ensure the viability of the benefits from Awards granted to Participants employed in such countries or jurisdictions, meet the requirements
that permit the Plan to operate in a qualified or tax efficient manner, comply with applicable foreign laws or regulations and meet the
objectives of the Plan.

 

		18.7	No Trust or Fund

 

The Plan is intended to constitute an “unfunded”
plan. Nothing contained herein shall require the Company to segregate any monies or other property, or shares of Common Stock, or to create
any trusts, or to make any special deposits for any immediate or deferred amounts payable to any Participant, and no Participant shall
have any rights that are greater than those of a general unsecured creditor of the Company.

 

		18.8	Successors

 

All obligations of the Company under the Plan
with respect to Awards shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct
or indirect purchase, merger, consolidation, or otherwise, of all or substantially all the business and/or assets of the Company.

 

		18.9	Severability

 

If any provision of the Plan or any Award is determined
to be invalid, illegal or unenforceable in any jurisdiction, or as to any person, or would disqualify the Plan or any Award under any
law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws, or, if it cannot
be so construed or deemed amended without, in the Committee’s determination, materially altering the intent of the Plan or the Award,
such provision shall be stricken as to such jurisdiction, person or Award, and the remainder of the Plan and any such Award shall remain
in full force and effect.

 

		18.10	Choice of Law and Venue

 

The Plan, all Awards granted thereunder and all
determinations made and actions taken pursuant hereto, to the extent not otherwise governed by the laws of the United States, shall be
governed by the laws of the State of California without giving effect to principles of conflicts of law. Participants irrevocably consent
to the nonexclusive jurisdiction and venue of the state and federal courts located in the State of California.

 

		18.11	Legal Requirements

 

The granting of Awards and the issuance of shares
of Common Stock under the Plan are subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies
or national securities exchanges as may be required.

 

SECTION 19. EFFECTIVE DATE

 

The effective date (the “Effective
Date”) is the date on which the Plan is adopted by the Board. In addition, to the extent necessary to comply with applicable
law, regulation or stock exchange rule, stockholder approval of the Plan shall be obtained

 

    19

     

    

 

APPENDIX A

 

DEFINITIONS

 

As used in the Plan, the following terms shall
be defined as provided below:

 

“Acquired Entity” means
any entity acquired by the Company or a Related Company or with which the Company or a Related Company merges or combines.

 

“Acquisition Price” means
the value of the per share consideration (whether consisting of cash, securities or other property, or otherwise) receivable or deemed
receivable upon a Change of Control in respect of a share of Common Stock, as determined by the Committee in its sole discretion. For
the avoidance of doubt, the Plan Administrator’s discretion will include determining whether and to what extent the Acquisition
Price will reflect any escrows, holdbacks, purchase price adjustments or other contingencies that occur after the closing of such Change
of Control and that affect the total consideration receivable or deemed receivable in respect of shares of Common Stock.

 

“Award” means any Option,
Stock Appreciation Right, Stock Award, Restricted Stock, Stock Unit or cash-based award or other incentive payable in cash or in shares
of Common Stock, as may be designated by the Committee from time to time.

 

“Board” means the Board
of Directors of the Company.

 

“Cause,” unless otherwise
defined in the instrument evidencing an Award or in a written employment, services or other agreement between the Participant and the
Company or a Related Company, means dishonesty, fraud, serious or willful misconduct, unauthorized use or disclosure of confidential information
or trade secrets, or conduct prohibited by law (except minor violations), in each case as determined by the Company’s chief human resources
officer or other person performing that function or, in the case of directors and executive officers, the Board, whose determination shall
be conclusive and binding.

 

“Change of Control,”
unless the Committee determines otherwise with respect to an Award at the time the Award is granted or unless otherwise defined for purposes
of an Award in a written employment, services or other agreement between the Participant and the Company or a Related Company, means the
occurrence of any of the following events:

 

(a) an
acquisition by any Entity of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than [50]%
of the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors
(the “Outstanding Company Voting Securities”); provided, however, that the following acquisitions shall not
constitute a Change of Control: (i) any acquisition directly from the Company, other than an acquisition by virtue of the exercise of
a conversion privilege where the security being so converted was not acquired directly from the Company by the party exercising the conversion
privilege, (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained
by the Company or any Related Company and (iv) any acquisition by any Entity pursuant to a transaction that meets the conditions of clauses
(i), (ii) and (iii) set forth in the definition of Company Transaction;

 

    A-1

     

    

 

(b) a
change in the composition of the Board during any two-year period such that the individuals who, as of the beginning of such two-year
period, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority
of the Board; provided, however, that for purposes of this definition, any individual who becomes a member of the Board subsequent to
the beginning of the two-year period, whose election, or nomination for election by the Company’s stockholders, was approved by
a vote of at least a majority of those individuals who are members of the Board and who were also members of the Incumbent Board (or deemed
to be such pursuant to this proviso) shall be considered as though such individual were a member of the Incumbent Board; and provided
further, however, that any such individual whose initial assumption of office occurs as a result of or in connection with an actual or
threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies
or consents by or on behalf of an Entity other than the Board shall not be considered a member of the Incumbent Board; or

 

(c) the
consummation of a Company Transaction.

 

“Code” means the Internal
Revenue Code of 1986, as amended from time to time.

 

“Committee” has the meaning
set forth in Section 3.1.

 

“Common Stock” means the
common stock, par value $0.00001 per share, of the Company.

 

“Company” means CYNGN
Inc., a Delaware corporation.

 

“Company Transaction,”
unless the Committee determines otherwise with respect to an Award at the time the Award is granted or unless otherwise defined for purposes
of an Award in a written employment, services or other agreement between the Participant and the Company or a Related Company, means consummation
of:

 

(a) a
merger, consolidation or similar corporate transaction of the Company in which the Company merges or otherwise combines with or into any
other company;

 

(b) a
statutory share exchange pursuant to which all of the Company’s outstanding shares are acquired or a sale in one transaction or
a series of transactions undertaken with a common purpose of all of the Company’s outstanding voting securities; or

 

(c) a
sale, lease, exclusive license, exchange or other disposition in one transaction, or a series of related transactions undertaken with
a common purpose, of all or substantially all of the Company’s assets,

 

excluding, however, in each case, any such transaction
pursuant to which

 

(i) the Entities who
are the beneficial owners of the Outstanding Company Voting Securities immediately prior to such transaction will beneficially own, directly
or indirectly, at least [50]% of the combined voting power of the then outstanding voting securities entitled to vote generally in the
election of directors of the Successor Company in substantially the same proportions as their ownership, immediately prior to such transaction,
of the Outstanding Company Voting Securities;

 

    A-2

     

    

 

(ii) no Entity (other
than the Company, any employee benefit plan (or related trust) of the Company, a Related Company or a Successor Company) will beneficially
own, directly or indirectly, more than [50]% of the combined voting power of the outstanding voting securities of the Successor Company
entitled to vote generally in the election of directors, unless such ownership resulted solely from ownership of securities of the Company
prior to such transaction; and

 

(iii) individuals who
were members of the Incumbent Board will immediately after the consummation of such transaction constitute at least a majority of the
members of the board of directors of the Successor Company.

 

Where a series of transactions undertaken with
a common purpose is deemed to be a Company Transaction, the date of such Company Transaction shall be the date on which the last of such
transactions is consummated.

 

“Compensation Committee”
means the Compensation Committee of the Board.

 

“Disability,” unless otherwise
defined by the Committee for purposes of the Plan or in the instrument evidencing an Award or in a written employment, services or other
agreement between the Participant and the Company or a Related Company, means a mental or physical impairment of the Participant that
is expected to result in death or that has lasted or is expected to last for a continuous period of 12 months or more and that causes
the Participant to be unable to perform his or her material duties for the Company or a Related Company and to be engaged in any substantial
gainful activity, in each case as determined by the Company’s chief human resources officer or other person performing that function or,
in the case of directors and executive officers, the Committee, each of whose determination shall be conclusive and binding.

 

“Effective Date” has the
meaning set forth in Section 19.

 

“Eligible Person” means
any person eligible to receive an Award as set forth in Section 5.

 

“Entity” means any individual,
entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Exchange Act).

 

“Exchange Act” means the
Securities Exchange Act of 1934, as amended from time to time.

 

“Fair Market Value” means
the closing price for the Common Stock on any given date during regular trading, or if not trading on that date, such price on the last
preceding date on which the Common Stock was traded, unless determined otherwise by the Committee using such methods or procedures as
it may establish.

 

“Grant Date” means the
later of (a) the date on which the Committee completes the corporate action authorizing the grant of an Award or such later date
specified by the Committee and (b) the date on which all conditions precedent to an Award have been satisfied, provided that conditions
to the exercisability or vesting of Awards shall not defer the Grant Date.

 

    A-3

     

    

 

“Incentive Stock Option”
means an Option granted with the intention that it qualify as an “incentive stock option” as that term is defined for purposes
of Section 422 of the Code or any successor provision.

 

“Incumbent Board” has
the meaning set forth in the definition of “Change in Control.”

 

“Nonqualified Stock Option”
means an Option other than an Incentive Stock Option.

 

“Option” means a right
to purchase Common Stock granted under Section 7.

 

“Option Expiration Date”
means the last day of the maximum term of an Option.

 

“Option Term” means the
maximum term of an Option as set forth in Section 7.3.

 

“Outstanding Company Common Stock”
has the meaning set forth in the definition of “Change in Control.”

 

“Outstanding Company Voting Securities”
has the meaning set forth in the definition of “Change in Control.”

 

“Parent Company” means
a company or other entity which as a result of a Company Transaction owns the Company or all or substantially all of the Company’s assets
either directly or through one or more subsidiaries.

 

“Participant” means any
Eligible Person to whom an Award is granted.

 

“Performance Award” means an
Award of Performance Shares or Performance Units granted under Section 11.

 

“Performance Share” means
an Award of units denominated in shares of Common Stock granted under Section 11.1.

 

“Performance Unit” means
an Award of units denominated in cash or property other than shares of Common Stock granted under Section 11.2.

 

“Plan” means the CYNGN
Inc. 2021 Incentive Plan.

 

“Prior Plan” has the meaning
set forth in Section 4.1(c).

 

“Related Company” means
any entity that, directly or indirectly, is in control of, is controlled by or is under common control with the Company.

 

“Restricted Stock” means
an Award of shares of Common Stock granted under Section 10, the rights of ownership of which are subject to restrictions prescribed
by the Committee.

 

“Restricted Stock Unit”
means a Stock Unit subject to restrictions prescribed by the Committee.

 

“Retirement,” unless otherwise
defined in the instrument evidencing the Award or in a written employment, services or other agreement between the Participant and the
Company or a Related Company, means “Retirement” as defined for purposes of the Plan by the Committee or the Company’s chief
human resources officer or other person performing that function or, if not so defined, means Termination of Service on or after the date
the Participant reaches “normal retirement age,” as that term is defined in Section 411(a)(8) of the Code.

 

    A-4

     

    

 

“Section 409A” means Section
409A of the Code.

 

“Securities Act” means
the Securities Act of 1933, as amended from time to time.

 

“Stock Appreciation Right”
or “SAR” means a right granted under Section 9.1 to receive the excess of the Fair Market Value of a specified
number of shares of Common Stock over the grant price.

 

“Stock Award” means an
Award of shares of Common Stock granted under Section 10, the rights of ownership of which are not subject to restrictions prescribed
by the Committee.

 

“Stock Unit” means an
Award denominated in units of Common Stock granted under Section 10.

 

“Substitute Awards” means
Awards granted or shares of Common Stock issued by the Company in substitution or exchange for awards previously granted by an Acquired
Entity.

 

“Successor Company” means
the surviving company, the successor company, the acquiring company or the Parent Company, as applicable, in connection with a Change
of Control.

 

“Termination of Service,”
unless the Plan Administrator determines otherwise with respect to an Award, means a termination of employment or service relationship
with the Company or a Related Company for any reason, whether voluntary or involuntary, including by reason of death, Disability or Retirement.
Any question as to whether and when there has been a Termination of Service for the purposes of an Award and the cause of such Termination
of Service shall be determined by the Company’s chief human resources officer or other person performing that function or, with respect
to directors and executive officers, by the Board, whose determination shall be conclusive and binding. Transfer of a Participant’s employment
or service relationship between the Company and any Related Company shall not be considered a Termination of Service for purposes of an
Award. Unless the Board determines otherwise, a Termination of Service shall be deemed to occur if the Participant’s employment or service
relationship is with an entity that has ceased to be a Related Company. A Participant’s change in status from an employee of the Company
or a Related Company to a nonemployee director, consultant, advisor or independent contractor of the Company or a Related Company, or
a change in status from a nonemployee director, consultant, advisor or independent contractor of the Company or a Related Company to an
employee of the Company or a Related Company, shall not be considered a Termination of Service.

 

“Vesting Commencement Date”
means the Grant Date or such other date selected by the Committee as the date from which an Award begins to vest.

 

    A-5

     

    

 

PLAN ADOPTION AND AMENDMENTS/ADJUSTMENTS

SUMMARY PAGE

 

	
    Date of

    Board Action
	 	
    

    Action
	 	
    Section/Effect
    of

 Amendment
	 	
    Date of 

Stockholder

    Approval

	September __, 2021	 	Initial Plan Adoption	 	 	 	September __, 2021Exhibit 10.6

 

CYANOGEN INC.

 

SECOND AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT

 

December 24, 2014

 

     

     

    

 

TABLE OF CONTENTS

 

	 	 	 	 	Page
	 	 	 	 	 
	1.	Definitions	 	1
	2.	Registration Rights	 	5
	 	2.1	Demand Registration	 	6
	 	2.2	Company Registration	 	6
	 	2.3	Underwriting Requirements	 	6
	 	2.4	Obligations of the Company	 	7
	 	2.5	Furnish Information	 	9
	 	2.6	Expenses of Registration	 	9
	 	2.7	Delay of Registration	 	9
	 	2.8	Indemnification	 	9
	 	2.9	Reports Under Exchange Act	 	11
	 	2.10	Limitations on Subsequent Registration Rights	 	11
	 	2.11	“Market Stand-off” Agreement	 	12
	 	2.12	Restrictions on Transfer	 	12
	 	2.13	Termination of Registration Rights	 	13
	3.	Information and Observer Rights	 	13
	 	3.1	Delivery of Financial Statements	 	13
	 	3.2	Inspection	 	15
	 	3.3	Observer Rights	 	15
	 	3.4	Termination of Information and Observer Rights	 	15
	 	3.5	Confidentiality	 	16
	4.	Rights to Future Stock Issuances	 	16
	 	4.1	Right of First Offer	 	16
	 	4.2	Termination	 	18
	5.	Additional Covenants	 	18
	 	5.1	Employee Agreements	 	18
	 	5.2	Employee Stock	 	18
	 	5.3	Qualified Small Business Stock	 	18
	 	5.4	Successor Indemnification	 	19
	 	5.5	Termination of Covenants	 	19
	6.	Miscellaneous	 	19
	 	6.1	Successors and Assigns	 	19
	 	6.2	Governing Law	 	20
	 	6.3	Counterparts	 	20
	 	6.4	Titles and Subtitles	 	20
	 	6.5	Notices	 	20
	 	6.6	Amendments and Waivers	 	20
	 	6.7	Severability	 	21
	 	6.8	Aggregation of Stock	 	21
	 	6.9	Additional Investors	 	21
	 	6.10	Entire Agreement	 	21
	 	6.11	Dispute Resolution	 	21
	 	6.12	Fees and Expenses	 	22
	 	6.13	Delays or Omissions	 	22
	 	6.14	Acknowledgement	 	22

 

	Schedule A	-	Series A Investors
	Schedule B	-	Series B Investors
	Schedule C	-	Series C Investors
	Schedule D	-	Schedule of Key Holders

 

     

     

    

 

SECOND AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT

 

THIS SECOND AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 24th day of December 2014, by and among Cyanogen Inc., a Delaware corporation
(the “Company”), each of the holders of Shares of the Company’s Series A Preferred Stock, par value $0.00001
per share (the “Series A Preferred Stock”) listed on Schedule A hereto (the “Series A Investors”),
each of the holders of Shares of the Company’s Series B Preferred Stock, par value $0.00001 per share (the “Series B Preferred
Stock”) listed on Schedule B hereto (the “Series B Investors”), each of the holders of Shares of the
Company’s Series C Preferred Stock, par value $0.00001 per share (the “Series C Preferred Stock,” and together
with the Series A Preferred Stock and Series B Preferred Stock, the “Preferred Stock”) listed on Schedule C
hereto (the “Series C Investors,” and together with the Series A Investors and the Series B Investors, the “Investors”)
and each of the stockholders listed on Schedule D hereto, each of whom is referred to herein as a “Key Holder”
and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section
6.9 hereof.

 

RECITALS

 

WHEREAS, the Company,
the Key Holders, the Series A Investors and the Series B Investors are party to that certain Amended and Restated Investors’ Rights
Agreement dated as of November 22, 2013 (the “Prior Rights Agreement”) and desire to amend and restate the Prior Voting
Agreement in accordance with Section 6.6 thereof;

 

WHEREAS, the Company
and the Series C Investors are parties to the Series C Preferred Stock Purchase Agreement of even date herewith (the “Purchase
Agreement”), pursuant to which the Series C Investors have agreed to purchase shares of Series C Preferred Stock; and

 

WHEREAS, the obligations
of the Company and the Series C Investors under the Purchase Agreement are conditioned on, among other things, the execution and delivery
of this Agreement by the parties hereto.

 

WHEREAS, the Company,
the Series A Investors, the Key Holders, and the Series C Investors desire to enter into this Agreement in order to amend, restate, and
replace the agreements and understandings of the parties under the Prior Rights Agreement with the agreements and understandings set forth
in this Agreement.

 

NOW, THEREFORE, the Company,
the Key Holders and the Investors agree as follows:

 

1.
Definitions. For purposes of this Agreement:

 

1.1 “Affiliate”
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any
venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the
same management company with, such Person.

 

    1

     

    

 

1.2
“Common Stock” means shares of the Company’s common stock, par value $0.00001 per share.

 

1.3 “Competitor”
means a Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture
or similar arrangement (whether now existing or formed hereafter)), in the Company’s line of business, but shall not include any
financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than 10% of the outstanding
equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the Board of Directors of
any Competitor.

 

1.4
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become
subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability
(or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material
fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to
be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the
indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any
rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

1.5 “Derivative
Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly),
Common Stock, including options and warrants.

 

1.6 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

1.7
“Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company
or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction;
(iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration
statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered.

 

1.8 “FOIA
Party” means a Person that, in the determination of the Board of Directors, may be subject to, and thereby required to disclose
non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552 (“FOIA”),
any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar
statutory or regulatory requirement.

 

    2

     

    

 

1.9
“Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form
under the Securities Act subsequently adopted by the SEC.

 

1.10 “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities
Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the
Company with the SEC.

 

1.11 “Holder”
means any holder of Registrable Securities who is a party to this Agreement.

 

1.12
“Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a
natural person referred to herein.

 

1.13 “Initiating
Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 

1.14 “IPO”
means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 

1.15
“Key Employee” means any executive-level employee of the Company.

 

1.16 “Key
Holder Registrable Securities” means (i) the 12,000,000 shares of Common Stock held by the Key Holders, and (ii) any Common
Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or
other distribution with respect to, or in exchange for or in replacement of such shares.

 

1.17 “Major
Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least 1,000,000
shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof).

 

1.18 “New
Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options,
or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable
into or exercisable for such equity securities.

 

1.19 “Person”
means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

1.20 “Preferred
Director Approval” means the approval of each of the Series A Director or the Series B Director (as such terms are defined in
the Restated Certificate).

 

    3

     

    

 

1.21
“Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock;
(ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities
of the Company, acquired by the Investors after the date hereof; (iii) the Key Holder Registrable Securities, provided,
however, that such Key Holder Registrable Securities shall not be deemed Registrable Securities and the Key Holders shall not be
deemed Holders for the purposes of Subsections 2.1, 2.10 and 6.6, and (iv) any Common Stock issued as (or issuable upon the conversion
or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange
for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities
sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and
excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement.

 

1.22 “Registrable
Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock
that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable
and/or convertible securities that are Registrable Securities.

 

1.23 “Restricted
Securities” means the securities of the Company required to bear the legend set forth in Subsection 2.12(b) hereof.

 

1.24 “SEC”
means the Securities and Exchange Commission.

 

1.25 “SEC
Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

 

1.26 “SEC
Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 

1.27 “Securities Act” means the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

1.28 “Selling
Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel
borne and paid by the Company as provided in Subsection 2.6.

 

1.29 “Special
Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least the number
of shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification
effected after the date hereof) equivalent to, based on the price at which each such share was originally purchased by the Investor, an
aggregate investment of $15,000,000.

 

    4

     

    

 

2.
Registration Rights. The Company covenants and agrees as follows:

 

2.1
Demand Registration.

 

(a) Form
S-1 Demand. If at any time after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180)
days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least a majority
of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least forty
percent (40%) of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of
Selling Expenses, would exceed $15 million), then the Company shall (x) within ten (10) days after the date such request is given, give
notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable,
and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder
to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection
2.1(c) and Subsection 2.3.

 

(b) Form
S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders
of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement
with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses,
of at least $10 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to
all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the
date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable
Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection
2.1(c) and Subsection 2.3.

 

(c) Notwithstanding
the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate
signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors
it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain
effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially
interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature
disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the
Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking
action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly,
for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however,
that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company
shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period
other than an Excluded Registration.

 

    5

     

    

 

(d) The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a) (i) during
the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that
is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company
has effected one registration pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of
Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b).
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i)
during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date
that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company
is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)
if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding
the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d)
until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw
their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration
statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected”
for purposes of this Subsection 2.1(d).

 

2.2 Company
Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders
other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely
for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration.
Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to
the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested
to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under
this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable
Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company
in accordance with Subsection 2.6.

 

2.3
Underwriting Requirements.

 

(a) If,
pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the
Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably
acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s
Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion
of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their
securities through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting
agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection
2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the
number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise
would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated
among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number
of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders;
provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall
not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in
accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest
one hundred (100) shares.

 

    6

     

    

 

(b) In
connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2,
the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders
accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters
in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities,
including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold
(other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering,
then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which
the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters
determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable
Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to)
the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such
selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round
the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall
(i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be
sold by the Company) are first entirely excluded from the offering, (ii) the number of Registrable Securities included in the offering
be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in
which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s
securities are included in such offering or (iii) notwithstanding (ii) above, any Registrable Securities which are not Key Holder Registrable
Securities be excluded from such underwriting unless all Key Holder Registrable Securities are first excluded from such offering. For
purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited
liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder,
or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the
benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with
respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included
in such “selling Holder,” as defined in this sentence.

 

2.4 Obligations
of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company
shall, as expeditiously as reasonably possible:

 

(a) prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts
to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier,
until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one
hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter
of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case
of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to
compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to 180 days, if necessary, to
keep the registration statement effective until all such Registrable Securities are sold;

 

    7

     

    

 

(b) prepare
and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such
registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered
by such registration statement;

 

(c) furnish
to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act,
and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;

 

(d) use
its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities
or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall
not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless
the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;

 

(e) in
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the underwriter(s) of such offering;

 

(f) use
its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a
national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued
by the Company are then listed;

 

(g) provide
a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration;

 

(h) promptly
make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration
statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial
and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees,
and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent,
in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate
due diligence in connection therewith;

 

(i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared
effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 

    8

     

    

 

(j) after
such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.

 

In addition, the Company
shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities
Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program
under Rule 10b5-1 of the Exchange Act.

 

2.5 Furnish
Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2
with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to
effect the registration of such Holder’s Registrable Securities.

 

2.6 Expenses
of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications
pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and
disbursements of counsel for the Company; and the reasonable fees and disbursements not to exceed $25,000, of one counsel for the selling
Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the
Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration
request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which
case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in
the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration
pursuant to Subsection 2.1(a) or Subsection 2.1(b), as the case may be; provided further that if, at the time of
such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from
that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such
information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant
to Subsection 2.1(a) or Subsection 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to
this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered
on their behalf.

 

2.7 Delay
of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2.

 

2.8 Indemnification.If
any Registrable Securities are included in a registration statement under this Section 2:

 

(a) To
the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors,
and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or
the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from
which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages
to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection
with such registration.

 

    9

     

    

 

(b) To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of
its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the
meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any
other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against
any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon
and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably
incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply
to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which
consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder
by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such
Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.

 

(c) Promptly
after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental
action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is
to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof.
The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory
to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented
without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure
to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying
party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices
the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it
of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8.

 

(d) To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party otherwise
entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined
(by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of
the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection
2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party
hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute
to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such
proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with
the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any
other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission
of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative
intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable
Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection
2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from
the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct
or fraud by such Holder.

 

    10

     

    

 

(e) Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into
in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.

 

(f) Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of
the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration
under this Section 2, and otherwise shall survive the termination of this Agreement.

 

2.8 Reports
Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of
the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration
on Form S-3, the Company shall:

 

(a) make
and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO;

 

(b) use
commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 

(c) furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement
by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective
date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the
Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant
to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any
Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the
Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company
so qualifies to use such form).

 

2.9 Limitations
on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent
of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder
of any securities of the Company that would provide to such holder the right to include securities in any registration on other than a
subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities
that they wish to so include or allow such holder or prospective holder to initiate a demand for registration of any securities held by
such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party
to this Agreement in accordance with Subsection 6.9.

 

    11

     

    

 

2.10 “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter,
during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares
of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending
on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case
of the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the
publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the
restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend;
offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option,
right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of
the IPO, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences
of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common
Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall only apply to the IPO,
shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders
only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain
a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock
(after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration
are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power, and authority to enforce the provisions
hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the
underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further
effect thereto.

 

2.11
Restrictions on Transfer.

 

(a) The
Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize
and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions
specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring
Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder
to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.

 

(b) Each certificate or
instrument representing (i) the Preferred Stock, (i) the Registrable Securities, and (iii) any other securities issued in respect of
the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be stamped or otherwise imprinted
with a legend substantially in the following form:

 

THE SECURITIES REPRESENTED HEREBY HAVE
BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED
IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.

 

THE SECURITIES REPRESENTED HEREBY MAY
BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH
THE SECRETARY OF THE COMPANY.

 

The Holders consent
to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to
implement the restrictions on transfer set forth in this Subsection 2.12.

 

    12

     

    

 

(c) The
holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions
of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration
statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s
intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale,
pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense
by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company,
addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii)
a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities
without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any
other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted
Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be
entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the
Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with
SEC Rule 144 or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration;
provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate or
instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to
SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate shall not bear such
restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance
with any provisions of the Securities Act.

 

2.12 Termination
of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to Subsection 2.1 or Subsection 2.2 shall terminate upon the earliest to occur of:

 

(a) the
closing of a Deemed Liquidation Event, as such term is defined in the Company’s Third Amended and Restated Certificate of Incorporation
(the “Restated Certificate”), in which the consideration received by the Investors is in the form of cash and/or marketable
securities;

 

(b) such
time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares
without limitation during a three-month period without registration; and

 

(c) the
fifth anniversary of the Qualified Public Offering (as defined in the Restated Certificate).

 

3.
Information and Observer Rights.

 

3.1 Delivery
of Financial Statements. The Company shall deliver to each Special Investor, provided that the Board of Directors has not reasonably
determined that such Special Investor is a competitor of the Company (provided that no Special Investor that is a venture capital
firm shall be deemed a competitor solely as a result of its investment in other companies):

 

(a) as soon as practicable, but in any event
within one-hundred twenty (120) days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such
year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end
of such year, all such financial statements to be prepared in accordance with generally accepted accounting principles
(“GAAP”) (provided that the Board of Directors (including the Preferred Director Approval) may waive the
requirement that such financial statements be prepared in accordance with GAAP) and audited and certified by independent public
accountants of nationally recognized standing selected by the Company, provided that no such audit shall be required for
fiscal year 2014;

 

    13

     

    

 

(b) as
soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal
year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement
of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements
may (i) be subject to normal year- end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with
GAAP), provided that the Board of Directors (including the Preferred Director Approval) may waive the requirement that such financial
statements be prepared in accordance with GAAP;

 

(c) Upon
request of a Special Investor as soon as practicable, but in any event within thirty (30) days after the end of each month, an unaudited
income statement and statement of cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared
in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain
all notes thereto that may be required in accordance with GAAP), provided that the Board of Directors (including the Preferred
Director Approval) may waive the requirement that such financial statements be prepared in accordance with GAAP;

 

(d) as
soon as practicable, but in any event forty-five (45) days before the end of each fiscal year, a budget and business plan for the next
fiscal year, prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and,
promptly after prepared, any other budgets or revised budgets prepared by the Company; and

 

(e) such
other information relating to the financial condition of the Company as any Special Investor may from time to time reasonably request;
provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that
the Company reasonably determines in good faith to be a trade secret or confidential information, or (ii) the disclosure of which would
adversely affect the attorney-client privilege between the Company and its counsel.

 

If, for any period,
the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial
statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company
and all such consolidated subsidiaries.

 

Notwithstanding anything
else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this Subsection 3.1
during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration
statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related
offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the
Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.

 

    14

     

    

 

3.2 Inspection.
The Company shall permit each Special Investor (provided that the Board of Directors has not reasonably determined that such Special
Investor is a competitor of the Company (provided that no Special Investor that is a venture capital firm shall be deemed a competitor
solely as a result of its investment in other companies)), at such Special Investor’s expense, to visit and inspect the Company’s
properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers,
during normal business hours of the Company as may be reasonably requested by the Special Investor; provided, however, that
the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and
in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement,
in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company
and its counsel.

 

3.3 Observer
Rights. As long as PI International Holdings LLC (“PI”) owns not less than twenty-five percent percent (25%) of
the shares of the Series C Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued
upon conversion thereof), the Company shall invite a representative of PI, who shall initially be Sandesh Patnam, to attend all meetings
of its Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices,
minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors;
provided, however, that such representative shall agree to hold in confidence and trust and to act in a fiduciary manner
with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information
and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting could
adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict
of interest, or if such Investor or its representative is a competitor of the Company (provided that PI shall not be deemed a competitor,
or to have a conflict of interest, solely as a result of its investment in other companies, except for any such company that could be
reasonably be viewed as a direct competitor of the Company). In the event Mr. Patnam shall cease to serve as the designated representative
of PI to attend all meetings of the Board of Directors in a nonvoting observer capacity, subject to the reasonable approval of the Board
of Directors, PI may designate another representative to serve in such capacity.

 

3.4 Termination
of Information and Observer Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3
shall terminate and be of no further force or effect (i) immediately before the consummation of a Qualified Public Offering, as such term
is defined in the Restated Certificate, (ii) when the Company first becomes subject to the periodic reporting requirements of Section
12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, in
which the consideration received by the Investors is in the form of cash and/or marketable securities, whichever event occurs first.

 

    15

     

    

 

3.5 Confidentiality.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor
its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including
notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes
known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor), (b) is or has been
independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been
made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have
to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants,
consultants, and other professionals to the extent reasonably necessary to obtain their services in connection with monitoring its investment
in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees
to be bound by the provisions of this Subsection 3.5; provided that (x) the Investor provides such prospective purchaser's
identity to the Company prior to any disclosure of confidential information and (y) the Board of Directors confirms in writing that it
has not reasonably determined that such prospective purchaser is a competitor of the Company; (iii) to any existing Affiliate, partner,
member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor
informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information;
or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes
reasonable steps to minimize the extent of any such required disclosure.

 

4.
Rights to Future Stock Issuances.

 

4.1 Right
of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the Company proposes
to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall
be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself,
(ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial
ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor (“Investor
Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner: (x) is not a Competitor or FOIA
Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, and (y) agrees to enter
into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the
Company, the Investors and the other parties named therein, as an “Investor” under each such agreement (provided
that any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor under Subsections 3.1, 3.2
and 4.1 hereof).

 

    16

     

    

 

(a) The
Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer
such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes
to offer such New Securities.

 

(b) By
notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or otherwise
acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion
that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon
conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor)
bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred
Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major
Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of
any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice,
each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares
specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed
for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly)
upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising
Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable,
of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed
shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date
that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c).

 

(c) If
all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b),
the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1, offer and
sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more
favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the
New Securities within such period, or if such agreement is not consummated within sixty (60) days of the execution thereof, the right
provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors
in accordance with this Subsection 4.1.

 

    17

     

    

 

(d) The
right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Restated Certificate);
(ii) shares of Common Stock issued in the IPO; (iii) the issuance of shares of Series C Preferred Stock to Additional Purchasers pursuant
to Subsection 1.3 of the Purchase Agreement; and (iv) the issuance of securities that, with unanimous approval of the Company’s
Board of Directors, are not offered to any existing stockholder of the Company.

 

4.2 Termination.
The covenants set forth in Subsection 4 shall terminate and be of no further force or effect (i) immediately before the consummation
of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange
Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, in which the consideration received
by the Investors is in the form of cash and/or marketable securities, whichever event occurs first.

 

5.
Additional Covenants.

 

5.1 Employee
Agreements. The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or
any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement, substantially
in the form approved by the Board of Directors.

 

5.2 Employee
Stock. Unless otherwise approved by the Board of Directors, all future employees and consultants of the Company who purchase, receive
options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first
twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares
vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar
to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, the Company shall retain a “right
of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at
cost upon termination of employment of a holder of restricted stock, and there shall be no provision for acceleration of vesting.

 

5.3 Qualified
Small Business Stock. The Company shall use commercially reasonable efforts to cause the shares of Series C Preferred Stock issued
pursuant to the Purchase Agreement, as well as any shares into which such shares are converted, within the meaning of Section 1202(f)
of the Internal Revenue Code (the “Code”), to constitute “qualified small business stock” as defined in
Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors
of the Company determines, in its good-faith business judgment, that such qualification is inconsistent with the best interests of the
Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may
be required under Section 1202(d)(1)(C) of the Code and the regulations promulgated thereunder. In addition, within twenty (20) business
days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver to such Investor a written
statement indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business
stock” as defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual information in the Company’s
possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest
in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code.

 

    18

     

    

 

5.4 Successor
Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not
the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall
be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members
of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be.

 

5.5 Termination
of Covenants. The covenants set forth in this Section 5, except for Subsection 5.4, shall terminate and be of no further
force or effect (i) immediately before the consummation of the IPO (ii) when the Company first becomes subject to the periodic reporting
requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s
Certificate of Incorporation, whichever event occurs first.

 

6.
Miscellaneous.

 

6.1 Successors
and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of
Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit
of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 500,000
shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations);
provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice
of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and
(y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of
this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable
Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s
Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member
shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify
individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices,
or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the
respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided herein.

 

    19

     

    

 

6.2 Governing
Law. This Agreement shall be governed by the internal law of the State of Delaware.

 

6.3 Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

6.4 Titles
and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.

 

6.5 Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or
facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s
next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid;
or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying
next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses
as set forth on Schedules A, B, C or D (as applicable) hereto, or to the principal office of the Company and
to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as
subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy
shall also be sent to Buddy Arnheim, 3150 Porter Drive, Palo Alto, CA 94304-1212 and if notice is given to Stockholders, a copy shall
also be given to Pillsbury Winthrop Shaw Pittman LLP, 2550 Hanover Street, Palo Alto, CA 94304, Attn: Armando Castro.

 

6.6 Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally
or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of
a majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance
with Subsection 2.12(c); and provided further that any provision hereof may be waived by any waiving party on such party’s
own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and
the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless
such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver
does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities
in such transaction). Further, this Agreement may not be amended, and no provision hereof may be waived, in each case, in any way which
would adversely affect the rights of the Key Holders hereunder in a manner disproportionate to any adverse effect such amendment or waiver
would have on the rights of the Investors hereunder, without also the written consent of the holders of at least a majority of the Registrable
Securities held by the Key Holders. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to
any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected
in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented
thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed
to be or construed as a further or continuing waiver of any such term, condition, or provision.

 

    20

     

    

 

6.7 Severability.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid,
illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent
permitted by law.

 

6.8 Aggregation
of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining
the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner
they deem appropriate.

 

6.9 Additional
Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company’s
Series C Preferred Stock after the date hereof, any purchaser of such shares of Series C Preferred Stock may become a party to this Agreement
by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor”
for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional
Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor”
hereunder.

 

6.10 Entire
Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement
among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof
existing between the parties is expressly canceled.

 

6.11 Dispute
Resolution. Any unresolved controversy or claim arising out of or relating to this Agreement, except as (i) otherwise provided in
this Agreement, or (ii) any such controversies or claims arising out of either party’s intellectual property rights for which a
provisional remedy or equitable relief is sought, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties,
and if no agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration
Association (the “AAA”), then by one arbitrator having reasonable experience in corporate finance transactions of the
type provided for in this Agreement and who is chosen by the AAA. The arbitration shall take place in the State of California, County
of San Mateo, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding
and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as follows:
(a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated,
(b) depositions of all party witnesses and (c) such other depositions as may be allowed by the arbitrators upon a showing of good cause.
Depositions shall be conducted in accordance with the laws of the State of Delaware, the arbitrator shall be required to provide in writing
to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting
the official transcript of such proceedings. The prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary
disbursements in addition to any other relief to which such party may be entitled.

 

    21

     

    

 

6.12 Fees
and Expenses. Subject to Section 6.11, if any action at law or in equity is necessary to enforce or interpret the terms of
the Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs, and necessary disbursements in addition
to any other relief to which such party may be entitled.

 

6.13 Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach
or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting
party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.

 

6.14 Acknowledgement.
The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and
related proprietary information of many enterprises, including enterprises which may have products or services which compete directly
or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing
or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the
Company.

 

[Signature Pages Follow]

 

    22

     

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.

 

	 	CYANOGEN INC.
	 	 
	 	By: 	/s/ Kirt McMaster
	 	 	Kirt McMaster-
	 	 	Chief Executive
	 	 
	 	Officer’s Address:
	 	516 High Street
	 	Palo Alto, CA 94301

 

SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above.

 

	 	Steven Kondik
	 	 
	 	By:	/s/ Steven Kondik
	 	 
	 	Address:  20182 110th Pl SE
	 	               Kent, WA 98031
	 	 
	 	Kirt McMaster
	 	 
	 	By:	 /s/ Kirt McMaster
	 	Address:  3003 Olin Avenue, #1 l 7
	 	               San Jose, CA 95128
	 	 
	 	Tom Moss
	 	 
	 	By: 	/s/ Tom Moss           
	 	Address:  94 Pepper Drive
	 	               Los Altos, CA 94022
	 	 
	 	Koushik Dutta
	 	 
	 	By: 	/s/ Koushik Dutta
	 	Address:  2929 1st Avenue 600
	 	               Seattle, WA 98121

  

SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date written above. 

 

	 	PURCHASER:
	 	 
	 	PI INTERNATIONAL HOLDINGS LLC
	 	 
	 	By: 	/s/ Rejesh Ramaiah         
	 	Name: 	 Rajesh Ramaiah
	 	Title: 	Authorized Signatory
	 	 
	 	Address:
	 	 
	 	455 N. Whisman Road, Suite 100
	 	Mountain View, CA 94043

 

SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date written above.

 

	 	ANDREESSEN HOROWITZ FUND III, L.P.
	 	for itself and as nominee for Andreessen Horowitz Fund III-A, L.P.,
	 	Andreessen Horowitz Fund III-B, L.P. and Andreessen Horowitz Fund III-Q, L.P.
	 	 	 
	 	By: 	AH Equity Partners III, L.L.C. 
	 	 	Its general partner
	 	 	 
	 	By:	/s/ Ben Horowitz
	 	Name: 	Ben Horowitz
	 	Title: 	Managing Member         
	 	 	 
	 	Address:
	 	 	 
	 	2865 Sand Hill Road Suite 101
	 	Menlo Park, CA 94025

 

SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date written above. 

 

	 	BENCHMARK CAPITAL PARTNERS VI, L.P.
	 	as nominee for
	 	Benchmark Capital Partners VI, L.P.,

                                                Benchmark Founders' Fund VI, L.P.,

                                                Benchmark Founders' Fund VI-B, L.P.

 and related individuals

	 	 	 
	 	By:	Benchmark Capital Management Co. VI,
	 	 	L.L.C., its general partner
	 	 	 
	 	By:	/s/ Mitch Lasky
	 		Managing Member
	 	 	 
		Address: 
	 	 	 
	 	2965 Woodside Road
	 	Woodside, CA 94062
	 	 	 
		BENCHMARK CAPITAL PARTNERS VII, L.P.
	 	as nominee for
	 	Benchmark Capital Partners VII, L.P.,

                                                Benchmark Founders' Fund VII, L.P.,

                                                Benchmark Founders' Fund VII-B, L.P.

	 	 	 
	 	By:	Benchmark Capital Management Co. VI, 
	 		L.L.C., its general partner
	 	 	 
	 	By:	/s/ Mitch Lasky
	 		Managing Member
	 	 	 
	 	Address:
	 	 	 
	 	2965 Woodside Road
	 	Woodside, CA 94062

 

SIGNATURE PAGE TO SECOND
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT CYANOGEN INC. 

 

     

     

    

 

IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first written above.

 

	 	OPH F LIMITED
	 	 
	 	By:	/s/ Martin Lau
	 	Name: 	 Lau Chiping Martin
	 	Title:	Authorized Representative
	 	 	 
	 	Address:
	 	 
	 	c/o Tencent Holdings Limited

                                             Level 29, Three Pacific Place

                                             No. 1 Queen's Road East

                                             Wanchai, Hong Kong

	 	Attn:	      Richard Pu
	 	 	 
	 	With a copy to:
	 	 
	 	Tencent Building
	 	Kejizhongyi Avenue, Hi-tech Park

                                             Nanshan District, Shenzhen, 518057

	 	P.R. China
	 	Attn:	     Bill Zhan

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above. 

 

	 	Redpoint Ventures IV,  L.P., by its General Partner
	 	Redpoint Ventures IV, LLC
	 	 
	 	Redpoint Ventures IV, LLC, as nominee
	 	 
	 	By: 	/s/ Scott C. Raney
	 	 	Scott C. Raney, Managing Director
	 	 
	 	Address:
	 	 
	 	3000 Sand Hill Road
	 	Building 2, Suite 290
	 	Menlo Park, CA 94025

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	Aviv Nevo
	 	 
	 	/s/ Aviv Nevo
	 	 
	 	Address:
	 	 
	 	301 Arizona Avenue
	 	Suite 310
	 	Santa Monica, CA 90401

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.

 

	 	JOHN HERING, TRUSTEE
	 	THE JOHN HERING LIVING TRUST
	 	 
	 	By: 	/s/ John Hering
	 	 	Trustee
	 	 
	 	Address:
	 	401 Harrison St #3903
	 	San Francisco, CA 94105

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	ROSEHEARTY INVESTMENTS LLC
	 	 
	 	By:	 /s/ Clare Sweeney
	 	Name:	 Clare Sweeney
	 	Title: 	Secretary

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	INDEX VENTURES VII (JERSEY), L.P
	 	 
	 	By: its Managing General Partner:
	 	Index Venture Associates VII Limited
	 	 
	 	/s/ Nigel Greenwood
	 	Nigel Greenwood
	 	Director
	 	 
	 	Address:
	 	Index Venture Associates VII Limited
	 	No 1 Seaton Place
	 	St Helier
	 	Jersey JE4 8YJ
	 	Channel Islands
	 	Attention: Danielle Cox
	 	Tel +44 (0) 1534 605749
	 	Fax +44 (0) 1534 605605
	 	 
	 	INDEX VENTURES VII PARALLEL
	 	ENTREPRENEUR FUND (JERSEY), L.P.
	 	 
	 	By: its Managing General Partner:
	 	Index Venture Associates VII Limited
	 	 
	 	/s/ Nigel Greenwood
	 	Nigel Greenwood
	 	Director
	 	 
	 	Address:
	 	Index Venture Associates VII Limited
	 	No 1 Seaton Place
	 	St Helier
	 	Jersey JE4 8YJ
	 	Channel Islands
	 	Attention: Danielle Cox
	 	Tel +44 (0) 1534 605749
	 	Fax +44 (0) 1534 605605

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	YUCCA (JERSEY) SLP
	 	 
	 	By: Elian Employee Services Limited as
	 	Authorised Signatory of Yucca (Jersey) SLP in
	 	its capacity as administrator of the Index Co-
	 	Investment Scheme
	 	 
	 	/s/ Elian Employment Benefit Services Limited
	 	Authorised Signatory – Elian Employment Benefit
	 	Services Limited
	 	 
	 	Address:
	 	 
	 	44 Esplanade
	 	St Helier
	 	Jersey JE4 9WG
	 	Channel Islands
	 	Facsimile +44 (0) 1534 504444
	 	Attention: Sarah Earles
	 	 
	 	With copies to:
	 	Index Venture Management S.A.
	 	2 rue de Jargonnant
	 	1207 Geneva
	 	Switzerland
	 	Fax +41 22 737 0099
	 	Attention: Andre Dubois

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	TWITTER, INC.
	 	 
	 	By:	 /s/ Richard Costolo
	 	Name:	 Richard Costolo
	 	Title:	Chief Executive Officer

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	Telefonica Open Future, S.L.U.
	 	 
	 	/s/ Ana Segurado Escudero
	 	By:	Ana Segurado Escudero
	 	Title:	 Director
	 	 
	 	/s/ Diego Colchero Paetz
	 	By:	Diego Colchero Paetz
	 	Title:	 Director

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	QUALCOMM Incorporated
	 	 
	 	By:	/s/ Adam Schwenker
	 	Name: 	 Adam Schwenker
	 	Title:	Vice-President and Legal Counsel

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	SALESFORCE.COM, INC.
	 	 
	 	By:	/s/ John Somorjai                     
	 	Name: 	 John Somorjai
	 	EVP, Corporate Development and
	 	Salesforce Ventures

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	AI Value Holdings, LLC
	 	 
	 	By Access Industries Management, LLC, its manager
	 	 
	 	By:	/s/ Peter L. Thoren
	 	Name: 	 Peter L. Thoren
	 	Title:	Executive Vice President
	 	 
	 	 
	 	By:	/s/ Richard B. Storey
	 	Name:	 Richard B. Storey
	 	Title:	Executive Vice President

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	BRYON EQUITIES CAPITAL LTD.
	 	 
	 	By:	 /s/ Lo, Tsung Kuei
	 	Name: 	 Lo, Tsung Kuei
	 	Title:	Director

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	SANTANDER FINTECH LIMITED
	 	 
	 	By:	/s/ Richard Brown
	 	Name: 	 Richard Brown
	 	Title:	Investment Director
	 	For and on behalf of Santander Fintech Limited

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	PAUL SHUSTAK
	 	 
	 	By:	 /s/ Paul Shustak

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	(If an Entity)
	 	 
	 	/s/ Nautilus Venture Partners, Fund I
	 	Entity
	 	 
	 	By:	 /s/ Connie Sheng
	 	Name: 	 Connie Sheng
	 	Title:	Managing Director
	 	 
	 	Address:
	 	 
	 	14904 Sobey Rd
	 	Saratoga, CA 95070

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	(If an Entity)
	 	 
	 	/s/ Rosy Ace Limited
	 	Entity
	 	 
	 	By:	 /s/ Peter Pan
	 	Name:	 Peter Pan
	 	Title:	Director
	 	 
	 	Address:
	 	 
	 	No. 4, Mingsheng Street
	 	Tucheng Dist., New Taipei City
	 	23679, Taiwan

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

 

	 	(If an Entity)
	 	 
	 	FOXTEQ HOLDINGS INC.
	 	Entity
	 	 
	 	By:	 /s/ Yu Huang, Chiu-Lian
	 	Name:	 Yu Huang, Chiu-Lian
	 	Title:	Director
	 	 
	 	Address:
	 	 
	 	No. 2, Ziyou Street, Tucheng District
	 	New Taipei City, 23678
	 	Taiwan

 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS'
RIGHTS AGREEMENT CYANOGEN INC.

 

     

     

    

 

SCHEDULE
A

 

SERIES A INVESTORS

 

	Name and Address	 	Shares of Series A Preferred Stock
    Held
	 	 	 
	
    Benchmark Capital Partners VII, L.P. 2965 Woodside Road

    Woodside, CA 94062
	 	8,038,585
	 	 	 
	Redpoint Ventures IV, L.P. 3000 Sand Hill Road Building 2,

Suite 290 Menlo Park, CA 94025	 	1,710,826
	 	 	 
	
    Redpoint Associates IV, LLC 3000 Sand Hill Road
Building 2,

Suite 290 Menlo Park, CA 94025
	 	43,847
	 	 	 
	
    TWB Investment Partnership II, L.P. 1201 Third Street, Floor
    49

    Seattle, WA 98101
	 	73,078
	 	 	 
	
    Terry K. Quan, P.C. 1239 Fernside Drive

    La Cañada Flintridge, CA 91011
	 	14,615
	 	 	 
	
    White Malula LLC 2131 22nd Street

    Santa Monica, CA 90405
	 	14,615
	 	 	 
	
    Jean-Paul Colaco Trust 223 13th Place

    Manhattan Beach, CA 90266
	 	73,078
	 	 	 
	
    Felix Anthony

    233 14th Avenue E, Apt. 107

    Seattle, WA 98112
	 	58,462
	 	 	 
	
    Michael Lee

    480 Cowper Street, Suite 280 Palo Alto, CA 94301
	 	58,462
	 	 	 
	
    William Flora

    615 17th Avenue E Seattle, WA 98112
	 	14,615

 

     

     

    

 

	Name
                                            and Address
	 	Shares
                                            of Series A Preferred Stock Held

	 	 	 
	
    Daniel Pepper

    2530 56th Avenue SW Seattle, WA 98116
	 	14,615
	 	 	 
	
    Eric Braff

    2530 56th Avenue SW Seattle, WA 98116
	 	14,615
	 	 	 
	
    Mark Gibson

    1826 E. Howell Street Seattle, WA 98122
	 	14,615
	 	 	 
	
    Robert Lee

    883 46th Avenue

    San Francisco, CA 94121
	 	14,615

 

     

     

    

 

SCHEDULE B 

 

SERIES B INVESTORS 

 

	Name
    and Address	 	Shares
    of Series B Preferred Stock Held
	 	 	 
	Andreessen Horowitz Fund III, L.P. 2865 

    Sand Hill Road, Suite 101	 	4,947,110
	Menlo Park, CA 94025	 	 
	Attn: Shawn Conway	 	 
	Email: shawn@a16z.com	 	 
	 	 	 
	Benchmark Capital Partners VII, L.P. 

    2965 Woodside Road	 	692,418
	Woodside, CA  94062	 	 
	Attn: Mitch Lasky	 	 
	Email: mitch@benchmark.com	 	 
	 	 	 
	Redpoint Ventures IV, L.P. 

    3000 Sand Hill Road	 	560,196
	Building 2, Suite 290	 	 
	Menlo Park, CA 94025	 	 
	Attn: Scott Raney	 	 
	Email: sraney@redpoint.com	 	 
	 	 	 
	Redpoint Associates IV, LLC 

    3000 Sand Hill Road	 	14,364
	Building 2, Suite 290	 	 
	Menlo Park, CA 94025	 	 
	Attn: Scott Raney	 	 
	Email: sraney@redpoint.com	 	 

 

     

     

    

 

	Name and
    Address	 	Shares
    of Series B Preferred Stock Held
	 	 	 
	OPH
    F Limited, a BVI Company	 	324,110
	c/o
    Tencent Holdings Limited	 	 
	Level
    29, Three Pacific Place	 	 
	No.
    1 Queen’s Road East	 	 
	Wanchai,
    Hong Kong	 	 
	Attn:
    Richard Pu	 	 
	Email:
    richardpu@tencent.com.hk	 	 
	 	 	 
	With
    a copy to:	 	 
	 	 	 
	Tencent
    Building	 	 
	Kejizhongyi
    Avenue, Hi-tech Park	 	 
	Nanshan
    District, Shenzhen, 518057	 	 
	P.R.
    China	 	 
	Attn:
    Bill Zhan	 	 
	Email:
    bill@tencent.com	 	 
	 	 	 
	TWB
    Investment Partnership II, L.P.	 	11,786
	1201
    Third Street, Floor 49	 	 
	Seattle,
    WA 98101	 	 
	Email:
    barnheim@perkinscoie.com	 	 
	 	 	 
	Terry
    K. Quan, P.C. 1239 Fernside Drive	 	2,210
	 	 	 
	La Cañada Flintridge,
    CA 91011	 	 
	Email: terry@foundationllp.com	 	 
	 	 	 
	Paul
    Shustak	 	2,210
	120 S. Sycamore Avenue	 	 
	Los Angeles, CA 90036	 	 
	Email: paulshu@yahoo.com	 	 
	 	 	 
	Donald
    Whitlatch	 	1,474
	501 Mystic Way	 	 
	Laguna Beach, CA 92651	 	 
	Email: whitco@cox.net	 	 
	 	 	 
	David
    J. Kondik II and Mandy E. Kondik, as	 	1,474
	joint tenants	 	 
	259 Scenery Drive	 	 
	Weirton, WV 26062	 	 
	Email: mandykondik@hotmail.com	 	 

 

     

     

    

 

	Name
and Address
	 	Shares
of Series B Preferred Stock Held

	 	 	 
	David J.
    Kondik and Joann R. Kondik 248 

Scenery Drive

    Weirton,
    WV 26062

    Email:
    jdkondik@hotmail.com
	 	1,474
	 	 	 
	Jose T.
    Suro

    3155 Frontera
    Way, #312

    Burlingame,
    CA 94010 

Email: jt1suro@hotmail.com
	 	1,474
	 	 	 
	Wayne Woods

    6670 Ambrosia
    Lane #522

    Carlsbad,
    CA 92011 wws2000@aol.com
	 	737
	 	 	 
	Eric Wise

    3445 Redwood
    Avenue Los Angeles, CA 

90066 Email: ewise@isbx.com
	 	1,474
	 	 	 
	Paul Wimmers
    949 Lake Street

    Venice,
    CA 90291

    Email:
    paulwimmers@hotmail.com
	 	737
	 	 	 
	Sheldon
    McMaster 74 Moxham Drive 

Sydney, Nova Scotia CANADA B1S 2A1

    Email:
    sheldonmcmaster@hotmail.com
	 	1,474
	 	 	 
	HoangYen
    T Nguyen 3003 Olin Ave Unit 

#117 San Jose CA 95128

    Email:
    yenhoang712@gmail.com
	 	1,474
	 	 	 
	Aileen
    Taylor 187 Somme SW Calgary, 

Alberta Canada T2T 5J8

    Email:
    aileenmarie@shaw.ca
	 	1,474 

 

     

     

    

SCHEDULE C

 

SERIES C INVESTORS

 

	Name and
    Address	 	Shares
    of Series C Preferred Stock Held
	 	 	 
	PI International
    Holdings LLC 455 N. 

Whisman Road, Suite 100 Mountain View, 

CA 94043

    Attn: Rajesh
    Ramaiah and Shruti 

Chandrasekhar

    Email:
    rajesh@premjiinvest.com;

 shruti@premjiinvest.com
	 	1,582,950
	 	 	 
	Andreessen
    Horowitz Fund III, L.P. 2865 

Sand Hill Road, Suite 101 Menlo Park, CA 

94025

    Attn: Shawn
    Conway 

Email: shawn@a16z.com
	 	287,718
	 	 	 
	Benchmark
    Capital Partners VI, L.P. 

2965 Woodside Road

    Woodside,
    CA 94062 

Attn: Mitch Lasky

    Email:
    mitch@benchmark.com
	 	290,162
	 	 	 
	Benchmark
    Capital Partners VII, L.P. 

2965 Woodside Road

    Woodside,
    CA 94062 

Attn: Mitch Lasky

    Email:
    mitch@benchmark.com
	 	217,622
	 	 	 
	OPH F Limited,
    a BVI Company 

c/o Tencent Holdings Limited 

Level 29, Three Pacific 

Place No. 1 Queen’s Road East Wanchai, Hong Kong

    Attn: Richard
    Pu

    Email:
    richardpu@tencent.com.hk
	 	18,850
	 	 	 
	With
    a copy to:	 	 
	 	 	 
	Tencent
    Building

    Kejizhongyi
    Avenue, Hi-tech Park Nanshan District, Shenzhen, 518057

    P.R. China
    Attn: Bill Zhan

    Email:
    bill@tencent.com
	 	 

 

     

     

    

 

	Name
and Address
	 	

    Shares
    of Series C Preferred Stock Held

	 	 	 
	Redpoint
    Ventures IV, L.P.

 3000 Sand Hill Road Building 2, 

Suite 290 Menlo Park, CA 94025 

Attn: Scott Raney

    Email:
    sraney@redpoint.com
	 	132,033
	 	 	 
	Redpoint
Associates IV, LLC 

3000 Sand Hill Road Building 2, 

Suite 290 Menlo Park, CA 94025 

Attn: Scott Raney

    Email:
    sraney@redpoint.com
	 	3,385
	 	 	 
	Aviv Nevo

    301 Arizona
    Avenue, 

Suite 310 Santa Monica, CA 90401

    Attn: Aviv
    Nevo 

Tel: 310-393-0934

    Email:
    vivi@nvinvestinc.com 

Email: office@nvinvestinc.com
	 	63,318
	 	 	 
	John Hering,
    Trustee of the John Hering Living Trust 401 Harrision Street, #3903

    San Francisco,
    CA 94105 

Attn: John Hering, Trustee

    Email:
    john.hering@lookout.com
	 	6,332
	 	 	 
	Rosehearty
    Investments LLC

    1211 Avenue
    of the Americas, 

8th floor New York, NY 10036

    Attn: Paula
    M. Wardynski 

Email: paulaw@21cf.com
	 	316,590
	 	 	 
	Index Ventures
    VII (Jersey), L.P.

    c/o Index
    Venture Associates VII Limited 

No 1 Seaton Place

    St Helier
    Jersey JE4 8YJ

    Channel
    Islands 

Attn: Danielle Cox

    Tel: +44
    (0) 1534 605749

    Fax + 44
    (0) 1534 605605
	 	152,150

 

     

     

    

 

	Name and
    Address	 	Shares
    of Series C Preferred Stock Held
	 	 	 
	Index Ventures VII Parallel
    Entrepreneur Fund (Jersey), L.P.	 	3,770
	Index Venture
    Associates VII Limited No 1 Seaton Place

    St Helier
    Jersey JE4 8YJ

    Channel
    Islands Attn: Danielle Cox

    Tel: +44
    (0) 1534 605749

    Fax + 44
    (0) 1534 605605
	 	 
	 	 	 
	YUCCA (JERSEY)
    SLP

    44 Esplanade
    St Helier

    Jersey
    JE4 9WG Channel Islands

    Facsimile
    +44 (0) 1534 504444 

Attn: Hollie Benec'h
	 	2,375
	 	 	 
	With copies to:	 	 
	 	 	 
	Index Venture
    Management S.A. 

2 rue de Jargonnant

    1207 Geneva
    Switzerland

    Fax: +41
    22 737 0099

    Attn: Andre
    Dubois
	 	 
	 	 	 
	Twitter,
    Inc.

    1355 Market
    Street, 

Suite 900 San Francisco, CA 94103

    Attn: Mike
    Gupta,

    Senior Vice President
	 	126,636
	 	 	 
	with copies to:	 	 
	 	 	 
	Attn: General Counsel twitterventures@twitter.com	 	 
	 	 	 
	QUALCOMM
    Incorporated 

5775 Morehouse Drive

    San Diego,
    CA 92121 

Attn: Adam Schwenker

    Email:
    aschwenker@qualcomm.com
	 	316,590

 

     

     

    

 

	Name and Address	 	Shares of Series C Preferred
    Stock Held
	 	 	 
	Salesforce.com,
    Inc.

    The Landmark
    @ One Market St., 

Suite 300 San Francisco, CA 94105

    Attn: John
    Somorjai, EVP Corporate Development

 Email: jsomorjai@salesforce.com
	 	316,590
	 	 	 
	AI Value
    Holdings, LLC c/o 

Access Industries, Inc.

    730 Fifth
    Avenue, 20th Floor New York, NY 10019

    Attn: Jared
    Fertman

    Email:
    jfertman@accind.com
	 	443,226
	 	 	 
	Telefónica
    Open Future, S.L.U. Ronda de la Comunicación s/n Distrito Telefónica, Edificio Oeste 2 28049 Madrid, Spain

    Attn: Ana
    Segurado Escudero

    Email:
    ana.seguradoescudero@telefonica.com

    Attn: Diego Colchero Paetz

    Email:
    dcolchero@telefonica.com
	 	158,295
	 	 	 
	Bryon Equities
    Capital Ltd. Vanterpool Plaza,

 2nd Floor, Wickhams Cay I,

    Road Town,
    Tortola, British Virgin Islands
	 	316,590
	 	 	 
	Notice to be provided to:	 	 
	 	 	 
	Roderick
    Purwana Chairman Office

    Sinarmas
    Land Plaza, Tower 2, Level 33

    Jl. MH.Thamrin
    51, Kav. 22, Jakarta Pusat 10350, Indonesia

    Email:
    roderick.purwana@sinarmas-agri.com
	 	 
	 	 	 
	Santander
    Fintech Limited 2 Triton Square

    London
    NW1 3AN United Kingdom

    Email:
    ants.secretariat@santander.co.uk 

Attn: Company Secretary
	 	158,295
	 	 	 
	Paul Shustak

    120 S.
    Sycamore Avenue Los Angeles, CA 90036

    Email:
    paulshu@yahoo.com
	 	1,583

 

     

     

    

 

	Name and
    Address	 	Shares
    of Series C Preferred Stock Held
	 	 	 
	Nautilus
    Venture Partners, Fund I 14906 Sobey Road

    Saratoga,
    CA 95070 Attn: Connie Sheng

    Email:
    connie@nautilusvp.com
	 	25,328
	 	 	 
	Rosy Ace
    Limited

    No. 4,
    Minsheng Street, Tucheng District New Taipei City

    23679

    Taiwan

    Attn: Francis
    C.H. Chen

    Email:
    francis.ch.chen@foxconn.com
	 	189,954
	 	 	 
	FOXTEQ
    HOLDINGS INC.

    No. 2,
    Ziyou Street, Tucheng District New Taipei City

    23678

    Taiwan

    Attn: Francis
    C.H. Chen

    Email:
    francis.ch.chen@foxconn.com
	 	126,636

 

     

     

    

 

SCHEDULE D

 

KEY HOLDERS

 

	Kirt McMaster	 	 
	3003 Olin Avenue, 

#117 San Jose, CA 

95128 

Email:
    kirt@cyngn.com	 	 
	 	 	 
	Steven Kondik 

20182 110th P1 

SE Kent, WA 

98031	 	 
	Email: steve@cyngn.com	 	 
	 	 	 
	Koushik Dutta	 	 
	2929 1st Avenue 600	 	 
	Seattle, WA 98121	 	 
	Email: koush@koushikdutta.com	 	 
	 	 	 
	Tom Moss	 	 
	97 Pepper Drive	 	 
	Los Altos, CA 94022	 	 
	Email: droid24601@gmail.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]